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“Only the atoms and the void are real” 
– Democritus (460 – 370 BC.) 
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“I don’t know what I want but I know how to get it” 
– Never mind the bollocks, here’s the Sex Pistol 
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Abstract 
Studying biological interactions at a molecular level is crucial to rationally 
interpret pathophysiological conditions. Several analytical techniques have been 
engaged to elucidate different aspects of biological systems and, depending on the 
research question, medicinal chemists need to select the most tailored problem-
solving approach. Among all possibilities, surface plasmon resonance (SPR) and 
circular dichroism (CD) spectroscopies offer intriguing potential. They can 
investigate both structural and functional aspects of biological targets and provide 
in return highly informative data output. In the present dissertation SPR and CD 
spectroscopies were employed to study different pharmaceutically relevant 
systems. The interaction between plant derivative Cucurbitacin, and serum 
albumins from different species (human and rat) was characterized with a 
combination of SPR direct binding assay and CD competition studies. 
Interestingly, two different binding profiles emerged. An extended SPR 
experimental set-up has been employed to investigate the interaction between the 
transcription factor from Helycobacter pylori NikR and the operator region of the 
urease promoter, revealing an isomerization of the protein–dsDNA complex 
occurring over time. SPR analysis was also employed to monitor the binding of 
Histone H4 residue to the methylation pocket of the epigenetic regulator SMYD3 
in the presence of a selected small molecule (BCI-121). Results support in silico 
and in cellulo findings, confirming competition for the same binding site. CD 
detection was employed in combination with high performance liquid 
chromatography to achieve a full stereochemical characterization of Trans-3-(3,4-
Dimethoxyphenyl)Glycidate enantiomers and to identify and quantify leva- and 
dexa-misole content in seized street cocaine samples. Studies reported in this 
dissertation highlighted how SPR and CD contribute to increase scientific 
knowledge on selected biological systems related to the field of life science. 
Moreover, assays developed here pose the basis for future inhibitors’ screening, 
which could eventually lead to the discovery of new chemical entities endowed 
with therapeutic properties. 
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Introduction 
New awareness in life science made us realize that complex, non-
communicable, diseases cannot be described by simplified pharmacological 
models and, in many cases, correlation with unique ligand–receptor binding events 
results sub-optimal1-3. In this scenario, receptors can be regarded just as small 
effectors in a complex network of communication, and interactions with different 
ligands can either trigger or quench specific activities. Nonetheless, it is fair to 
state that drug discovery is still based on the profound knowledge of the biological 
system we want to modulate, and to the thorough inspection of the entire set of 
actors involved in the network. This is arguably the best strategy to produce a 
solid, rationally design, therapeutic strategy. Advancement in technology has made 
available for medicinal chemists increasingly sophisticated analytical techniques 
that allow detailed description of biomechanisms and biostructures. Therefore, 
among all options available, the operator has now to make the decision on how and 
when take advantage of the most appropriate methods to answer different 
questions across many biological systems. 
Spectroscopy is the study of how matter interacts with any portion of the 
electromagnetic spectrum4. Scientists have been investigating for centuries how 
physicochemical environments influence electromagnetic radiations and different 
spectroscopic-based techniques have been developed. Among them, surface 
plasmon resonance (SPR) and circular dichroism (CD) offer intriguing 
experimental approaches for both structural and dynamic characterization. SPR-
based analysis is steadily gaining recognition in both academia and industry in 
view of their versatility and highly informative data output. Typical analysis can 
detect thermodynamic and kinetic parameters of binding events employing just 
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few µg of biomaterial. CD spectroscopy is a well-established analytical technique 
for structural characterization of molecules either free or bound, in solution. In 
many cases can be considered the best option to elucidate binding modes, if 
crystals structures are not available. 
The present dissertation includes a collection of experimental works in which 
SPR and CD were employed to elucidate significant aspects of pharmaceutically 
relevant systems. Basic concepts and principles of biochemistry and 
pharmaceutical analysis are also illustrated.  
The introductive Chapter 2 briefly describes how the concept of ligand–
receptor interaction evolved during the last centuries, and how it has been linked to 
the insurgence of physiologic effects. Modern comprehension of living organisms 
prompted the birth of refined receptor theories able to better-forecast affinity–
activity relationship with respect to classic models. These innovative approaches, 
take into consideration the complexity of the open-system physiology and the 
constant fluctuations of substances in different body compartments. However, no 
theory can be tested without analytical platforms able to directly measure 
quantities in a molecularly scaled system. To this scope, examples of the both 
classical and more recently developed analytical methodologies are illustrated in 
chapter 3. This latter introduces the main area of operation, structural and 
functional characterization of bioactive compounds, and will set the framework for 
the introduction of SPR and CD technologies. Chapter 4 and chapter 5 feature 
description of CD and SPR in term of detection principle, instrumentation 
available, experimental set up and data analysis. It is important to note that only 
information relevant for the experimental investigations included in this 
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dissertation are provided; while, for in depth description, readers are referred to 
excellent literature throughout the text. 
Following the introductive section, the present dissertation will include extracts 
from studies published in peer-reviewed journals and will highlight how the state-
of-the-art was taken over by further investigations through the analytical 
technologies SPR and CD. Original articles were adapted and reprinted with 
permission from the publishers. All SPR and CD results were obtained from 
experiments carried out during the course of the PhD program. However, each 
manuscript comprehends different analytical approaches and a complete 
description of all the trials performed will results out of the scope of the present 
dissertation. Nevertheless, they will be mentioned and commented to better frame 
how and where SPR and CD were employed. Readers that wish to consult material 
and methods for the analytical methodologies other than SPR and CD can directly 
refer to the original articles. 
In the first extract, chapter 6, SPR biosensing and CD spectroscopy were 
employed to characterize the interaction of naturally occurring triterpenoids – 
Cucurbitacins – with serum albumin form different species for early ADME 
profiling. The binding of exogenous and endogenous compounds to serum proteins 
can impact their distribution volume, an issue that needs to be carefully assessed in 
translational medicine. Despite cucurbitacins can be considered as high affinity 
binders towards rat and human serum albumin, two different affinities and binding 
mode were identified in the two different species. Chapter 7 includes an extensive 
SPR analysis of the interaction between the transcription factor from Helycobacter 
Pylori NikR and its dsDNA target sequence, the promoter region of the urease 
operator – OPureA. The extended experimental set-up employed, in combination 
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with isothermal titration calorimetry (ITC) data, resulted extremely useful to 
uncover a high affinity binding in the presence of Nickel in the environment. 
Moreover, the method developed could be useful to screen for inhibitors of a 
protein–DNA interaction, which are usually hard to screen for, thus they were 
previously defined as undruggable. In chapter 8 a stopped-flow enantioselective 
high performance liquid chromatography-circular dichroism detection (HPLC-CD) 
methods was developed for the separation of methyl trans-3-(3,4-
Dimethoxyphenyl) Glycidate enantiomers. Then, by combination with time-
dependent density functional theory (TD-DFT) calculation, a full stereochemical 
characterization of the eluted fractions was achieved. The application of CD 
detection was also described in chapter 10, where levamisole and tetramisole 
presence in seized cocaine samples was revealed and quantified by the same 
experimental set-up. In this instance the selectivity of the detection method 
allowed monitoring dexamisole and levamisole in complex mixture as street drug 
samples. The extract presented in chapter 9, highlights the use of SPR biosensing 
to support molecular docking and in cell inhibition assay for an oncogenic target, 
SMYD3. In this study, a small molecule was selected through virtual screening 
and then tested for effectiveness in a selected cell line. The binding of the small 
molecule to SMYD3 methylation pocket was confirmed, indirectly, through a 
competition in solution assay. 
Chapter 11 is a brief conclusion that will summarize all the findings and will 
indicate some of the future perspectives hinted by the present dissertation. 
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How in vitro affinity correlates with in vivo activity? 
Every physiological and pathological effect stems from a well-defined 
interaction between two or more chemical entities. Humanity unconsciously knew 
this paradigm for millennia, and despite molecules were something far beyond 
knowledge in ancient times, it was known that assumption of natural products 
could produce well-defined physiological effects5.  
In his book from 1690 – Essay concerning human understanding – John Locke 
wrote: 
 ‘Did we but know the mechanical affections of the 
particles of rhubarb, hemlock, opium and a manywe 
should be able to tell beforehand that rhubarb will purge, 
hemlock kill and opium make a man sleepy…’ 
 
now we can see that those ‘mechanical affections’ described by John Locke are 
nothing but the ‘chemical interactions’ as we intend them in the present days. 
However, neither description of their intrinsic nature nor comprehension of their 
mechanism of action was attempted. 
The first breakthrough came from Emil Fisher in 1896, when he introduced the 
lock-and-key theory6. This model implies that pathophysiological effects are due 
to invisible microscopic events taking place within human body and these events 
are produced by the encounter of two physical entities granted with the same 
specificity and distinctiveness as the ones showed by the key and its lock. In 1908, 
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Paul Ehrlich coined the iconic expression “corpora non agunt nisi fixata”. This 
aphorism means “molecules can’t exert their [physiological] effect unless they are 
[physically] bound [to the receptor]”. Ehrlich conducted pioneeristic studies on 
arsenic derivatives for syphilis treatment; his research clearly proved that small 
chemical modifications of organic molecules could modulate both therapeutic and 
undesired effects, producing the first example of structure-activity relationship 
(SAR) study7. Following Ehrlich discoveries, in 1950, R. P. Stephenson 
formulated the first theoretic descriptions of biomolecular interactions. He 
introduced the concept of active and non-active conformation of an 
enzyme/receptor and discerned the in vitro binding affinity from the in vivo 
activity8. 
The groundwork of Fisher, Ehrlich, Stephenson and their contemporary 
colleagues, had provided medicinal chemists with a new, great, pharmacological 
tool: Equilibrium dissociation constant (KD). KD is by definition the concentration 
of ligand necessary to occupy 50 % of receptor population in a steady state 
condition that is when the total concentration of each reactant remains constant 
over time. It is considered the cornerstone of drug discovery: the tighter the ligand 
binds its target in an in vitro assay, the higher its efficacy can be in an in vivo 
system. Similarly, steady state inhibition constant Ki and parameter IC50 describe 
the half-maximal inhibitory concentration in enzymatic assays, in which dimming 
of a given biological activity is monitored while sequentially adding inhibitor at 
increasing concentrations.  
Major goal for medicinal chemists can be considered the identification, either 
from natural compounds or commercially available databases, of favorite 
molecular structure able to bind the desired target with low-to-moderate affinity. 
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Subsequently, through synthetic chemistry the scaffold is modified in order to 
achieve higher efficient binders to bring to pre-clinical and clinical trials. During 
this process the guidelight is KD (or Ki) value for the ligand–analyte complex; 
increasing stability indicates modifications improved binding efficiency and could 
potentially improved in vivo activity.  
However, despite being the conditio sine qua non for efficacy, KD and Ki values 
measured for several bimolecular complexes fails to quantitatively correlate with 
in vivo activity, and the relationship observed in many cases is rather qualitative9 
(Fig. 1a). This ambiguous behavior can be sought in the nature of physiological 
systems; there is no body compartment, no tissue nor cells that rests in a perfect 
steady state condition. Physiology is a dynamic process, and we know that drug 
concentration fluctuates both locally and globally within human body. 
 
Figure 1 | In vivo efficacy often depends on drug-target residence time. The relationship 
between the residence time of a series of Fabl enoyl‐reductase inhibitors and in vivo activity. The 
plots presented here show the percent survival of mice 10 days after they were infected with the 
bacterium Francisella tularensis and then treated with the inhibitors. a | Correlation of percent 
survival with the inhibition constant (Ki). b | Correlation of percent survival with inhibitor 
residence time. (Figure is adapted with permission from ref [10]). 
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Once entered circulatory stream, compounds undergo a complex network of 
interactions that comprehend many different binding partners along with the 
primary one. In the open system of in vivo pharmacology (Fig. 2b), multiple steps 
such as absorption, distribution and clearance affect the local concentration of 
ligand that arrives at the receptor-harboring tissue and consequently the rate of 
encounter with its primary target10. Therefore, individual rate constants defining 
the steady state affinity value (KD = koff / kon) acquire new significance, and 
dissociative half-lives of the multiple complexes need to be assessed and 
interpreted. 
KD values are usually determined in closed systems (Fig. 2a); therefore, the 
time-dependent variation of compound concentration is not always taken into 
account. Residence time (τ) can provides further insight on the affinity–activity 
relationship. τ expresses the time ligand is associated with the receptor and can be 
directly obtained as the reciprocal function of the dissociation rate constant (τ = 
1/koff) of a bimolecular complex (Fig. 2c). It has been demonstrated that for many 
biological systems, τ better describes the in vivo potency of a drug with respect to 
steady state affinity measurements9, 10 (Fig 1b). Slow dissociating complexes can 
exists beyond the complete excretion of the ligand from the body and the related 
physiological effect can lengthen considerably; moreover, in many cases higher τ 
reflects higher selectivity thus less toxicity. Excellent materials reporting the 
significance of residence time for efficacy and selectivity can be found in many 
excellent articles throughout the literature11-15. Residence time gains even more 
relevance when receptor isomerization is considered. In this situation after the first 
encounter between the two binding partners to form the first complex (R + L ⇒ 
RL), a rearrangement leads to a more stable conformation (RL ⇒ RL*) that cannot 
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directly dissociates into the first two interactants. In this case, the term koff is 
composed of microscopic rate constants associated with both forward and reverse 
steps in receptor isomerization, koff = koff1koff2/(koff1 + kon2 + koff2)10 (Fig 2d).  
 
 
Figure 2 | Representative illustration of ligand–receptor kinetic interactions. Receptor is 
depicted as a red square and the ligand as a blue circle. (a) In a closed system concentration of all 
interactants remain constant over the time required for the experiment, therefore a real condition of 
equilibrium can be established. (b) Conversely, in the open-system, fluctuation dominates and 
distribution, metabolism, and clearance all affect the concentration of drug in the receptor-
harboring tissue. This does not allow reaching a true steady-state condition. (c) Classic scheme of a 
reversible 1:1 binding mechanism, with associated forward and backwards reaction constants kon 
and koff. (d) Scheme for a two-step binding mechanism, where receptor isomerization occurs. Two 
additional forward/backward rate constants are present, kon2 and koff2, that accounts for the 
conformational switch of the bimolecular complex. 
 
This behavior was detected while studying the interaction between the 
transcription factor from helycobacter pylori – HpNikR and the dsDNA of the 
urease operator – OPureA (see chapter 7). Upon binding to OPureA in presence of 
four Ni(II) equivalents, HpNikR showed a behavior consistent with an induced-fit 
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mechanism, where its structure rearranges over time to form a more stable 
complex with the dsDNA sequence. The conformational rearrangement of the 
HpNikR– OPurea complex over time was linked to a physiologic adjustment of the 
bacteria to high Nickel content in the environment16. 
Nevertheless, no chemical interaction can be seen by unaided eye, and 
analytical techniques are necessary to directly or indirectly interrogate binding 
events at molecular level. 
 22  
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Analytical techniques allow structural and functional characterization of 
biological systems 
Biological systems have always being questioned through different approaches. 
The common objective is to identify specific features of the target and define its 
biological role in a precise network of communications. Afterwards, 
pharmacological hypothesis are proposed and scrupulous experiments are designed 
to test their consistency. From data analysis, structure-activity relationships are 
sketched and iterative processes of trials and errors can eventually lead to the 
discovery of new chemical entities endowed with therapeutic properties. 
The advent of molecular biology freed scientists from the burden of laboriously 
collect milligrams of bioactive materials from living organisms able to 
spontaneously create it. Current technology allows biological targets to be 
efficiently produced and retrieved from engineered microorganisms programmed 
to express determined exogenetic material17-19. Pharmaceutical science greatly 
benefited from this revolution and at present day, in many instances, we possess 
enough material so that detailed bioanalyses can be carried out. 
Biological targets can be scrutinized at different levels; however, we can mainly 
profile their structural and functional features. Structural characterizations aim to 
define the tridimensional space of macromolecules, so structure-based drug 
discovery can be carried out. In this scenario, analytical techniques usually capture 
snap-shots of the receptor/enzyme alone or in combination with 
endogenous/exogenous ligands. The insight they provide can guide modifications 
of chemical scaffolds, based on new hot spots discovered within binding sites, or 
aids to rationalize biorecognition events through visualization of chemical 
environments.  
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On the other hand, functional characterization aims to profile their behavior 
with respect to the interaction with different binding partners. Initial 
biorecognition studies are usually carried out in cell-free assays to define 
thermodynamic and kinetic parameters of the ligand–receptor reaction. 
Subsequently, same binding events are probed on in vivo systems, to check for 
translation of primary affinity into a more physiologically-like setting. 
Throughout the years a vast plethora of analytical approaches have been 
employed for structural and functional characterization. Each technique is engaged 
to uncover specific aspects of the biorecognition process and early drug discovery 
undoubtedly benefits from their complementary and synergy. As a representative 
sample of all the available options it worth to mention equilibrium dialysis20-22, 
analytical ultracentrifugation23, 24, ultrafiltration25, affinity capillary electrophoresis 
(ACE)26, 27, nuclear magnetic resonance (NMR)28-30, circular dichroism (CD)31-34 
and fluorescence spectroscopies35-37, quartz crystal microbalance (QCM)38, 39, 
high-performance affinity liquid chromatography (HPALC)40, 41, X-ray 
crystallography 42, 43, mass spectrometry (MS)44-46, small angle light scattering 
(SAXS)47, surface acoustic wave (SAW)48 and surface plasmon resonance (SPR)-
based biosensors49-51, isothermal titration calorimetry (ITC)52-54, cryo-electronic 
microscopy (cryo-EM)55, 56 and microscale thermophoresis (MST)57-59. 
X-ray crystallography can be considered the chief technique in the structural 
field. It has been successfully employed for the structural characterization of 
thousands of biomolecular structures and for the establishment of modes of action 
of many ligand–receptor systems43. Recently, cryo-EM has emerged as an 
alternative approach56. Cryo-EM measures electron diffraction patterns of 
biomolecules embedded in a cryogenic media, without requiring pre-staining or 
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fixation of any kind. Therefore, images can be collected in specimen natural 
environments without risking alteration of the overall molecular structure. Also 
MS has been employed to resolve many macromolecular structures both at the 
primary and at higher orders; moreover, combination with limited proteases 
digestion enables identification of unknown protein through fragments analysis45. 
For thermodynamic characterization, ITC is considered the most suited 
technique in view of its ability to directly measure enthalpy (∆H) of ligand–
receptor binding events and stoichiometry (n) and stability (KD) of binary 
complexes in solution. The heat released or absorbed during a reaction is measured 
upon titration of one of the two interactants, usually protein or DNA, with 
increasing concentration of the other, usually a small organic molecule. 
Nonetheless, it requires high material consumption a condition that is not always 
easy to achieve during early stages of drug discovery54. MST can characterize 
ligand–receptor affinity in a vast array of situations including solubilized 
membrane proteins, provided that on of the two binding partners is fluorescently 
labeled or intrinsically fluorescent. Measurements are directly related to the 
movement of particles in a thermal gradient: every shift due to the variation of 
hydrodynamic range or to a conformational rearrangement upon association 
between molecules can be detected and used to quantify binding events57. Other 
techniques such as SPR, QCM and SAW allow extrapolation of reactions kinetic 
parameters applying continuous flow of analyte/buffer over an immobilized 
interactant60, 61. They all possess the ability to detect interactions in real-time, 
generating association/dissociation traces that can be analyzed through application 
of theoretic binding models. Each technology exploits different physical 
transducers: SPR monitors the shift of refractivity at the surface of a biosensor 
chip, QCM measures changes in the vibration frequency of a quartz crystal and 
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SAW detect perturbation in frequency and amplitude of acoustic waves. As 
common features they quantified KD, kon, koff and thermodynamic parameters. 
More recently, in silico techniques started providing additional tools for both 
structural and functional studies. Computational chemistry can be employed to 
simulate 3D environments of proteins and calculate free energy of reactions, hence 
aiding to understand biomechanisms and prioritize favorite chemical structures62-64. 
Whenever dealing with huge libraries of molecules, as in the present era of 
combinatorial chemistry and fragment-based drug discovery, virtual screening can 
drastically reduce time needed for optimization of compounds, easing the rational-
design of molecules by synthetic chemists65. 
Circular dichroism (CD) and surface plasmon resonance (SPR) spectroscopies 
are two detection methods particularly intriguing for biochemical analyses; they 
can provide both structural and functional information depending on the 
experimental set up employed for the study. SPR detection emerged as an efficient 
approach to obtain large amounts of information about binding processes. Simple, 
automated and fast assays provide good throughput, versatility and highly 
informative data output, rendering the methodology particularly suited for early 
drug discovery61. CD analysis can be considered the élite technology to study 
conformation of bioactive molecules in solution either bound or free. Intrinsic 
chirality of nature lends well itself to CD analysis; asymmetric disposition of 
atoms can be interrogated to elucidate binding modes and stereoselectivity, even 
when previous crystal structure or in silico models are not available66. 
In the following sections, these two analytical methodologies are presented in 
details and their principal features thoroughly described. 
 28  
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4. Circular dichroism spectroscopy (CD) 
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Detection principle 
The branch of spectroscopy that studies the interaction of ultraviolet and visible 
light with matter is called UV-vis spectroscopy and energy of the associated 
electromagnetic radiation is responsible for transitions of electrons from ground 
states to excited states67-70 (Fig 3). 
 
Figure 3 | Graphical representation of the whole electromagnetic spectrum. The colored inset 
depicts the region where visible light is located. Different molecular transitions are associated with 
different energies: γ-rays nuclear, x-rays core level electrons; UV-vis valence electrons; 
IR=infrared molecular vibrations; Microwaves molecular rotations, electron spin; Radio waves 
nuclear spin; (Adapted with permission from ref [67]).  
 
According to quantum theory, only specific groups of atom posses the correct 
spatial arrangement to interact with UV-vis light and only some specific electronic 
transitions in them are allowed. Chemical groups possessing these specific features 
are defined chromophores and are responsible of colors displayed by organic and 
inorganic molecules. 
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Usually, light sources as the sun or incandescent light bulbs, generate 
unpolarized electromagnetic radiation, meaning they produce an incoherent 
random mixture of transverse waves (Electric and Magnetic) propagating in space 
with multiple frequencies, wavelengths and directions. Some devices, defined 
polarizers, can polarize the electromagnetic radiation to the extent it propagates 
only in one direction, i.e. oscillates only over one plane71, 72 (Fig. 4). 
 
Figure 4 | Depiction of the electronic component of the electromagnetic radiation propagating in 
space. Linear, circular and elliptical polarization states are presented. 
 
Circular polarization is a polarization state wherein the electric field of the 
wave has a constant magnitude but its direction rotates in a fix plane perpendicular 
to the direction of the wave propagation73 (Fig 4). The rate of this rotation remains 
constant in time, and the shape of the resulting light vector describes a helix. 
Circularly polarized light can be right-handed circularly polarized light, if the 
vector rotates clockwise, or left-handed circularly polarized light if the vector 
rotates counterclockwise, with respect to an observer towards which the light is 
directed.  
Linearly polarized light is usually produced by combination of two 
perpendicular electromagnetic waves of the same amplitude and frequency 
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propagating in phase relative to one another. Optical elements, termed 
quarter‐wave plate, are able to converts linearly polarized light in circularly 
polarized light, and vice versa74. In a quarter‐wave plate, one of the linear 
components of the beam will slow with respect to the other, so that they are one 
quarter‐wave out of phase and a beam of either left‐ or right‐circularly polarized 
light is produced. 
When right and left circularly polarized lights are shone through a transparent 
chamber containing a chiral sample, they can be absorbed differently due to the 
intrinsic asymmetry of atoms disposition in the molecule73. Direct measurements 
of the unequal absorption produce CD spectra, while measuring the ellipticity [θ] 
of the emerging light results in optical rotatory dispersion spectra (ORD). 
   
Figure 5 | Graphical representation of the interaction of light with a helical charge 
displacement. (redesigned from ref. [75]). (a) Left-handed helical charge displacement interacts 
preferentially with right circularly polarized light resulting in negative CD. (b) Right-handed 
helical charge displacement interacts preferentially with left circularly polarized light resulting in 
positive CD. 
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The different interaction, at atomic level, resides in the charge displacement 
upon absorption of the radiation (Fig. 5). The motion of the excited electrons from 
the ground state to the excited state generates a helical electric field that can be left 
or right handed depending on the spatial arrangement of atoms around the 
chromophore. Circularly polarized light has a similarly helical electric field, and 
preferential interactions occur between the two helical fields: left handed charge 
displacement interacts preferentially with right circularly polarized light, right 
handed charge displacement with left circularly polarized light75 (Fig. 5). 
AS a consequence, CD spectra of pure enantiomers differ in sign, but not in 
magnitude, while non-chiral molecules or racemic mixtures will not show any CD 
signal73, 76 (Fig. 6).  
 
Figure 6 | Representative CD spectra of captopril A (1-[(2S) 3-mercapto-2-methylpropionyl]-
(S)-proline) and its stereoisomers. A clear mirror-image relationship between absorption bands 
appear for the two couple of enantiomers. Adapted and modified from Ref [76].  
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Lambert-Beer law describes the differential absorption of right and left 
circularly polarized light: 
 ∆A = AL − AR = εLcl − εRcl = ( εL − εR )cl = ∆εcl  (1) 
where ∆ε is the molar differential extinction coefficient. ORD and CD have the 
same quantum information content; therefore, ∆ε and θ° are intimately connected 
according to the relationship: 
  [θ ] ≅ 3300∆ε   (2) 
A CD spectrum is the plot of ∆ε over a range of wavelengths while ORD is the 
plot of the ellipticity. Both of them provide valuable insight on chirality; yet, the 
former is by far the most employed in view of its lower tendency to be affected by 
light artifacts and its direct wavelengths-correspondence with absorption bands. 
Although CD phenomenon can occur throughout the entire spectra of 
electromagnetic radiation, the ones related to valence electrons absorption are the 
most relevant to the study of organic molecules. This form of circular dichroism is 
defined as electronic circular dichroism (ECD). 
 
Instrumentation 
Spectropolarimeters are the instruments employed to assess chiral properties of 
molecules. They are derived from classic spectrophotomers with the addition of 
devices suited for the production, modulation and detection of circularly polarized 
light. In principle, a CD spectrum of a molecule can be measured in two separate 
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experiments: the sample is irradiated first with one and then with the other beam of 
circularly polarized light, and the differential absorption is recorded. However, 
from an experimental point of view, the best mode is through polarization 
modulation77. With this technique circularly polarized light, is gradually switched 
through all the ellipticities between 0 ° and ± 180°, through harmonic variations of 
the potential alternate current (AC) voltage on electro-optic modulators. This 
modulator is inserted into the workflow of the spectropolarimeter, before the 
sample chamber. The other typical components of a spectroplarimeter are 
described below: 
• Light source: generally a combination of deuterium and tungsten lamps, able to 
produce light ranging from 150 nm up to 800 nm. 
• Monochromator: usually a prism or a diffraction grating that allows the passage 
of only a narrow wavelength range (called spectral bandwidth). The orientation of 
the prism/grating dictates the wavelength of the emerging light. 
• Polarizer: usually a Rochon polarizer producing pure polarized light.  
• Photon electron modulator: through application of alternate current voltage 
modulates the handedness of the circularly polarized light directed to the sample 
chamber. 
• Sample chamber: Cells made of fused silica to circumvent the UV-absorbing 
impurities of glass. This area can be thermostated. 
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• Detector: usually a photomultiplier or a photodiode array device, whose signals 
are amplified and directed to a recorder or computer. Absorbance data are 
processed as a function of incident wavelength to give an absorption spectrum. 
A graphical representation is shown in figure 7. 
 
Figure 7 Graphical representation of a spectropolarimeter. (Adapted from reference [77]).  
 
Experimental set-up 
CD effects are strictly related to UV-vis light absorption of the sample; 
therefore experimental optimizations aim to minimize artifacts arising from other 
sources of absorption, dispersion and diffraction of the incident light. 
The utmost consideration should be given to the sample composition. Firstly, 
chemical species need to be fully solubilized; if otherwise, recorded absorbance 
might be due to light scattering, i.e. events related to the fine dispersion of particles 
in solution rather then electronic transition in the chromophore moisture68, 78. Then, 
it is important to choose the proper buffer. As general rule, buffer composition 
should be kept as simple as possible, however in some circumstances additives 
cannot be left out. Small organic molecules might demand non-polar solvents to 
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aid solubilization, while biomolecules, as proteins and DNA, usually need salts 
and proper buffering agents. Requirements are more flexible for small molecules, 
while it is sometimes impossible to remove precise components from 
macromolecules media if their functionality wants to be preserved. As far as the 
protein is the main concern some alternatives can be explored, and salt and buffer 
might be changed to favor spectroscopic properties79. Spectroscopic contribution 
of common buffers and salts are reported in table 1. 
Since absorbance is governed by the Lambert-beer law, its amplitude can be 
modulated according to the length (l) of the sample cell. If this parameter is 
reduced sufficiently, and the protein concentration can be kept high enough, 
problems due to solvent absorption might be overcome. Additionally, the range of 
wavelength for the measurement has to be carefully assessed according to the 
chromophore we want to excite. Different chemical groups absorb in different 
regions of the UV-vis spectra, therefore different structural features are probed at 
different energies. 
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Absorbance (50 mM solution in 0.02 cm pathlength) 
COMPONENT 180 nm 190 nm 200 nm 210 nm 
NaCl > 0.5 > 0.5 0.02 0 
NaF 0 0 0 0 
NaClO4 0 0 0 0 
Boric acid 0 0 0 0 
Na borate (pH 9.1) 0.3 0.09 0 0 
Na2HPO4 > 0.5 > 0.3 0.05 0 
NaH2PO4 0.15 0.01 0 0 
Na acetate > 0.5 > 0.5 0.17 0.03 
Tris/H2SO4 (pH 8.0) > 0.5 0.24 0.13 0.02 
HEPES/Na+(pH 7.5) > 0.5 > 0.5 0.5 0.37 
MES/Na+(pH 6.0) > 0.5 0.29 0.29 0.07 
Table 1. Absorption of selected buffer components in the UV region. (Data from ref [79]). 
 
However, it is difficult to make measurements much below 190 nm, partly 
because the intensity of the radiation falls off in this region, but also because N2 
used for purging the sample compartment, optical devices and aqueous solvents 
absorb significantly78. 
To check how strongly the chemical environment contributes to the overall 
absorbance, a blank sample, containing all but the molecules whose absorption 
wants to be measured, is run before the actual measurement take place. 
Along with sample-related considerations, also instrument setting can improve 
quality of the CD analysis. Parameters that can be adjusted are listed below: 
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• Bandwidth: The bandwidth is a measure of the precision with which a 
monochromator selects light of a chosen wavelength. Increasing the bandwidth 
will allow more light to fall on the sample and hence on the photomultiplier, but 
will decrease the ability to resolve spectral bands. The bandwidth should be less 
than or equal to 1 nm for routine CD studies, but values down to 0.1 nm are useful, 
particularly to resolve fine structure in the near UV spectrum of proteins. 
• Time constant and scan rate: The time constant is a measure of the time over 
which the CD data are averaged and will depend on the precise mode of operation 
of the instrument. 
 • Number of scans: Increasing the number of scans will improve the signal/noise 
(S/N) ratio; the S/N ratio is proportional to the square root of the number of scans. 
However, a universal guideline can’t be proposed, and parameters needs to be 
set on case-by-case basis, taking into account any limitations imposed by the 
stability of the sample under the conditions employed, and the performances of the 
instrument.  
One relevant experimental set up concerning CD spectroscopy is its 
combination with liquid chromatography (HPLC-CD), as experimentally 
illustrated in the present dissertation (chapter 10) and in literature80-82. The 
hyphenation of a separation technique (HPLC) with a chiral detection system 
(CD), allows recognition of optically active samples among crowded UV-
absorbing mixtures. This methodology was successfully employed to determine 
the enantiomeric composition of tetramisole enantiomers in seized cocaine 
samples, where the direct selective monitoring of levamisole and dexamisole 
through CD detection was enabled even in the presence of possible interferences81.  
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Moreover, HPLC-CD system offers the possibility to exploit on-line detection 
approach. This is achieved by trapping a chromatographic peak into a tailored CD 
sample chamber so that its CD spectrum can be measured over a range of 
wavelengths. This provides a valuable analytical tool that allows determination of 
CD spectra for compounds directly eluting from a chromatographic run and avoid 
the time-consuming step of collecting and dry out pure enantiomers for complete 
CD characterization. This latter approach revealed its suitability for the 
stereochemical characterization of different chemical species and in the present 
dissertation was applied to elucidate chirooptic properties of trans-glycidate 
enantiomers 82, 83(see chapter 8). 
 
Data output and analysis 
Generally, a CD signal will be detected if a molecule shows chiral features, i.e. 
the molecule is optically active84. Reasons behind optical activity can be one of the 
following: 
• A chromophore is intrinsically chiral because of its chemical structure. For 
instance a Carbon atom with 4 different substituents  
• The chromophore is covalently bound to a chiral centre in the molecule  
• The chromophore lies in an asymmetric environment dictated by the overall 
structure of the molecule. 
All these properties cause the electronic transition from the ground states to the 
excited states to be affected by an asymmetric disposition of electronic clouds in 
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the chemical environment; hence, chiral light beams (helices light vectors show 
their own chirality) will favor some transitions over others. 
CD will appear in correspondence of absorption bands; therefore, they are 
easily ascribed to specific chromophoric groups. For instance, peptide bond 
absorbs below 240 nm (π → π* transition centered around 190 nm and n → π* 
transition around 220 nm), aromatic amino acid absorbs in the range 260 – 320 
nm, and other coordinated systems found in many organic molecules such as 
flavons and chlorophyll will absorbs up to the near infrared region. Generally, the 
wider is the coordinate system of chromophores, the longer will be the wavelength 
of absorption (Benzene 255nm, Naphthalene 286nm, Anthracene 375nm; 
Naphthacene 477nm)68. 
Chirality is intrinsically related to bioactive molecules: life building blocks and 
actuators are very often chiral such as L-aminoacids and D-sugars. As a result, 
macromolecules will show their own chiral signatures, due to the highly ordered 
3D disposition of small chiral blocks in the macromolecules’ structure85, 86. CD 
spectra and X-ray crystals for several proteins have been obtained and correlated, 
so that many CD reference databases are now available. By means of algorithms, 
these databases can be consulted to quantitatively estimated content of secondary 
structures from the CD spectra measured in solution85, 87. CD spectra aroused by 
common secondary structures habitually found in protein are displayed in figure 8. 
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Figure 8 | (a) CD spectra of poly-L-lysine and placental collagen in different conformations. poly-
L-lysine: 1 (black) α-helical; 2 (red) antiparallel β-sheet; 3 (green) extended conformations. 
Placental collagen: 4 (blue) native triple-helical and 5 (cyan) denatured forms. (b) CD spectra of 
representative proteins with varying conformations: 1 (black) sperm whale myoglobin; 2 (green) 
chicken heart lactate dehydrogenase; 3 (red) bovine α-chymotrypsin and 4 (cyan) human Bence 
Jones protein REI light chain, which is a human immunoglobulin light chain of κ type. (Reprinted 
with permission from ref. [87]). 
 
Despite main application area for secondary structures analysis can be 
considered quality control of protein production (batch-to-batch assessment of 
protein folding), it can also provide valuable information on biologic processes. 
In the wake of some diseases, crucial proteins can mutate their physiologic 
folding and pathologic conditions can emerge. This was observed for the Amyloid 
beta protein that switches its conformation from mainly alpha-helix to mainly beta-
sheets in high-water-content media over time88 or the refolding of prion proteins 
induced by phosphorilation89. Monitoring these events in the presence or absence 
of specific compounds can indicate if any delay in the conformational switched 
occurred, thus forecasting therapeutic properties90.  
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Other molecules that do not normally show CD spectra, can gain optical 
activity if constrained into a fixed conformation due for example to the inclusion 
into a chiral protein binding site. This peculiar form of CD is defined as induced 
circular dichroism (ICD) and can be a useful tool for monitoring ligand–receptor 
binding events91 (Fig. 9). Non-chiral molecules that gain ICD upon specific 
binding with proteins can be employed as markers for that binding site, and their 
ICD can be monitored to extrapolate unique information on the absolute 
configuration of chiral molecules as well as the orientation of molecules relative to 
each other within the host-guest complex66, 92, 93. 
 
Figure 9 | Example of induced circular dichroism (ICD). UV/vis (a) and circular dichroism (b) 
spectra of curcumin–AGP complex in solution at different ligand/protein ratios (cell length 1 cm, 
conentration of AGP 130 µM, T= 15 °C). Ligand protein rations are indicated in the figure. The 
more curcumine bounds to AGP to form the complex, the greater the intenstity if the ICD bands 
become. Reprinted and adapted with permission from ref [92]. 
 
Moreover, careful data analysis can provide invaluable tool to determine 
binding strength and direct or indirect competition for a determined binding site. 
This approach was particularly useful for the characterization of Cucurbitacins–
Serum albumin molecular interaction (see chapter 6)94 where two different binding 
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modes were identified for the triterpenoids binding to serum protein from rat and 
human. This behavior is an indication of a potential different pharmacokinetic 
profile of the compound when tested in different animal models, an issue that 
needs to be carefully assessed in translational medicine.  
Finally, it is important to mention that combination of experimental CD 
analysis with quantum chemical calculations, based on time-dependent density 
functional theory (TD-DFT), can provide additional information on 
stereochemistry82. UV and CD spectra can be predicted through in silico analysis 
and compared to experimental measurements to assign absolute configurations to 
CD profiles. This method demonstrates to be valid over a wide range of bioactive 
molecules and in this dissertation resulted useful for the assignment of the absolute 
configuration of two enantiomers contained in samples obtained from root extracts 
of different species of comfrey and bugloss (see chapter 8). 
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5. Surface plasmon resonance spectroscopy 
 
 
This chapter is based on: H. U. Danielson, E. Fabini “Monitoring drug–serum proteins interaction 
for early ADME prediction through Surface Plasmon Resonance based technology” (2017) 
Journal of Pharmaceutical and Biomedical Analysis – Accepted for publication 26 Mar 2017– 
 
Doi: 10.1016/j.jpba.2017.03.054 
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Detection principle and optical configuration 
The optical phenomenon of SPR occurs when a beam of plane-polarized light 
hits the surface of a thin, electron-rich, metal layer placed at the interface between 
two media of different refractive indices (n1 ≠ n2)95. At a specific angle of 
incidence (θ), under condition of total internal reflection (TIR), the photons of the 
light are able to excite the (nearly) free electron gas of the metal, causing 
excitation of surface plasmons. This plasmon state is a highly delocalized state 
resulting in a resonant, non-radiative, wave at the interface between the metal and 
the dielectric medium95 (Fig 10). 
 
Figure 10. Illustration of optical configuration for the excitation of surface plasmons in metals (the 
configuration illustrated here is termed Kretschmann).  
 
This wave has an evanescent nature, with a penetration depth around 300 nm in 
the sample chamber. In this condition, the photons–plasmons coupling dissipate 
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energy and the intensity of the reflected light recorder by a detector attenuates, 
resulting into a sharp minimum in the angle-dependent reflectance. This is, 
experimentally, the primary recorded quantity96. 
If all parameters such as wavelength, intensity of light and temperature are kept 
constant, the angle θ at which the excitation of surface plasmons occurs is solely 
based on the refractivity. When the refractive index of the media n2 is perturbed, 
for instance as consequence of mass accumulating at the immediate proximity of 
the metal layer, the angle θ shifts, and the position of the dip minimum shifts 
accordingly.  
In commercially available SPR biosensors that employ the Kretschmann 
configuration, the metal is a 50 nm thick gold layer, and the two media are a glass 
prism (n1) and the solution flowing in the microfluidic cartridge (n2), 
respectively97. In a typical SPR experiment, a biological target (ligand) is tethered 
to the surface of a sensor chip, through chemical modification of the gold film 
facing the fluidic side, and the analyte is injected over the surface, free in solution 
(Fig 11). 
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Figure 11 | Schematic representation of the SPR detection principle. The SPR angle Θ, when 
all other parameters are kept constant, is dependent only on the refractive index of the solution in 
proximity of the functionalized surface. Upon interaction between the analyte and the ligand, the 
refractivity at the surface changes, resulting in changes in Θ. The magnitude can be directly 
correlated to the amount of complex formed. 
 
As a consequence of the ligand–analyte interaction, refractivity of the media n2 
changes, equilibrium condition is perturbed and a response arises. This response is 
quantified, typically plotted as the change in refractivity (refractivity/response 
units, RU) over time resulting in a sensorgram (Fig. 12). 
A shift of 1 RU corresponds approximately to a change in surface density of 1 
pg/mm2 and a consequent variation of 0.0001° of the SPR angle θ. This allows 
direct quantification of complex formation98, 99. The close dependence between the 
amount of material bound to the surface, and the shift of the SPR angle θ, has been 
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demonstrated to be valid, with excellent approximation, regardless of the chemical 
species involved100. 
 
Figure 12 | Typical data output from an SPR experiment. The real-time interaction curve, 
named sensorgrams, represents an accurate description of the interaction between the tethered 
ligand and free-flowing analyte. Non-linear regression analysis of sensorgram shapes can be used 
to extrapolate the rate of association (kon) and dissociation (koff) of the binding event. Responses 
(expressed in response units – RU), reached at steady-state can be used to construct the isotherm of 
binding and determine the equilibrium dissociation constant KD of the ligand–analyte complex. 
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Instrumentation 
Different optical configurations have been employed to investigate molecular 
binding events through SPR phenomena. The so-called Kretschmann configuration 
was used to develop a vast array of SPR platforms, both in the traditional and in 
the imaging (SPRi) format51, 101-104. More recently, an alternative SPR 
configuration, termed localized SPR (LSPR) has emerged. With this mode, SPR is 
generated on the surface of a nanoparticle rater than a metal film, endowing 
completely new spectroscopic properties to the metal depending on nanoparticle 
composition, size, shape, orientation and local dielectric environment. Thanks to 
the miniaturization potential, LSPR-based devices are viewed as affordable, 
portable and easy-to-use tool for point-of-care testing105, 106. Nonetheless, to 
discuss the present thesis BIAcore-related instrumentations are the most relevant 
and therefore they will be presented in details. 
In BIAcore platforms (Kretschmann configuration), the gold layer of the sensor 
is typically functionalized with a dextran hydrogel, resulting in a three-
dimensional support available for the immobilization through chemical 
modification. This provides a flexible support for various methods of 
immobilization of proteins or other molecules used to define the sensor surface. 
Moreover, it constitutes a coat that prevents non-specific adsorption of 
molecules107, 108. To meet different experimental requirements, various commercial 
sensor surfaces have been developed, each one tailored to exploit different 
immobilization chemistries. For a complete overview of all sensor chips available, 
please refer to the BIAcore surfaces handbook [BR-1005-71 AB 05/2008]. 
A microfluidic system creates a series of flow channels wherein different 
ligands can be immobilized. This forms a sensor chip surface, with multiple 
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detection spots. An accurate, automated device ensures the inclusion of the sensing 
surface into the system and a close contact between the fluidics and the optical 
detection unit. This compartment is precisely thermostated and not directly 
accessible for the operator during the experiment. Analyte solutions are delivered 
to the surface by automated injection, and a liquid handling system that precisely 
controls the flow of buffer and samples. Depending on the platform employed, 
fluidics, sensitivity and throughput might vary, with top quality products 
possessing adequate characteristics for fragment library screening. Material 
consumption is typically very low, and for a complete analysis, only a few 
micrograms of both the ligand and the analyte are required109.  
 
SPR experiments 
A complete SPR experiment requires two main steps: 1) the immobilization of 
one of the two interactants on the sensing surface, termed preparative step, and 2) 
the investigation of a given interaction through real-time monitoring, termed 
analytical step.  
Immobilization – preparative step 
The immobilization procedure can be considered the most challenging part of 
the experimental set-up, since the ligand needs to retain its biological activity upon 
anchorage to the surface. Given the wide variation in molecular properties, no 
generally applicable immobilization method has emerged. Rather different 
approaches may be needed in order to reach the required activity110. In this thesis, 
the description is limited to the amine coupling and the affinity capture procedures, 
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representative of the strategies employed to carry on the different experiments. A 
complete description of all the available techniques can be found in the handbook 
of surface plasmon resonance. 
Amine coupling procedure is based on the formation of a covalent bond 
between the primary amines exposed on the surface of the ligand (i.e. Lysine) and 
the carboxyl groups of the carboxylated dextran surface (Fig. 13). 
 
Figure 13 | Representative scheme for amine coupling procedure, with the three basic steps: 1) 
activation with EDC/NHS, 2) ligand injection and 3) deactivation of the surface. 
 
The ligand needs to be dissolved into a weakly acidic, low ionic strength 
solution -1 pH unit below the pI of the ligand – to achieve enough electrostatic 
concentration at the dextran layer, before the linking reaction takes place. 
Exploiting the negative charges on the acidic groups of the surface and the positive 
charges of the residues of the ligand, the two chemical entities are drawn near in 
space. The whole procedure comprises three sequential steps, the activation of the 
surface, the injection of the ligand and the deactivation of the residual active 
groups on the surface. The first step consists in the injection of a mixture of 1-
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Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
Hydroxysuccinimide (NHS) that generates active esters, then through a 
nucleophilic attack, the primary amines of the protein substitute the esters forming 
a stable amide bond. Since the reaction leaves some unreacted esters, they need to 
be quenched. This is achieved through the deactivation step, which is performed 
with Ethanolamine. 
Amine coupling is usually able to guarantee high immobilization levels and 
highly stable sensor chip surfaces. However, the sometimes-harsh conditions 
needed for the pre-concentration step may affect the ligand activity, and if Lysines 
are close to the active site of the protein may hamper its functionality. This 
approach was employed to prepare human and rat serum albumin sensing surfaces 
(chapter 6).  
Immobilization procedure through affinity capture approach relies on the 
affinity between a capture molecule, covalently attached to the surface (ex. 
antibody, streptavidin), and the target molecules, which is injected, captured and 
then used as ligand. The capture molecule recognizes either a tag or a specific 
epitope of the target molecule, with an affinity able to guarantee enough complex 
stability to perform an experiment (Fig. 14). 
This approach bears some advantages over the classical amine coupling 
procedure. Even though the immobilization level is usually less than what can be 
achieved through amine coupling, and the ligand can leak from the surface over a 
long period, the procedure can be performed in proteins’ natural buffer. 
Furthermore, with this procedure we can orient the ligand on the surface, ensuring 
that the active sites are exposed and available for the reaction. This overcomes the 
intrinsic heterogeneity at the surface introduced by the amine coupling. This 
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approach was employed for SMYD3 and OPureA immobilizations (see 
experimental section). 
 
Figure 14 | Illustration of the affinity capture procedure. The capturing molecule (antiGST 
antibody in this istance) is covalently attached to the surface and the ligand (GST) is capture 
through high-affinity binding. 
 
Interaction analysis – analytical step 
The most-employed approach to perform SPR-based interaction analyses is to 
anchor the protein on the polymer and to flow the low-molecular-weight analyte 
over it. This represents a typical direct binding-assay, where different compounds 
are probed against the same target. Nevertheless, other assay formats have been 
developed and established.  
For instance, in-solution competition can be performed to see if compounds 
compete for the same binding site on the surface111, 112. For instance, large 
molecules (e.g., proteins), which possess an intrinsically high SPR signal, can 
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compete with small molecules (e.g., therapeutic agents), which feature low SPR 
signal; SPR responses are lowered considerably when small molecules bind 
stronger than large molecules, providing a tool to rank inhibition capacity for 
selected compounds and qualitatively estimate their inhibition capacity. This 
approach was useful to support molecular biology in a drug discovery project 
concerning the epigenetic target SMYD3 project (chapter 9) and to confirm the 
suitability of the SPR assay to test inhibition of the HpNikR–OPureA interaction 
(chapter 7). 
The experimental conditions are optimized by selecting a suitable buffer and 
regeneration conditions, the latter needed for slowly dissociating complexes. The 
concentration range of the analyte needs to be carefully selected, as it is dependent 
on both the solubility of the compound and its affinity for the ligand. Ideally, the 
range should cover concentrations comprise between 0.1 · KD and 10 · KD. 
Whenever possible, it is important to include a positive and a negative control in a 
binding assay. This is to avoid artifacts due to unrelated phenomena that produce a 
change in refractivity, such as unspecific adsorption to the chip surface or to the 
protein scaffold, which results in an SPR signal. Careful experimental design and 
data analysis is crucial for success113. 
There are two main injection modes to performed an interaction analysis using 
SPR-based biosensors 1) Multi-cycle injections or 2) Single-cycle injections114 
(Fig. 15). 
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Figure 15 | Representative sensorgrams of (a) classical multi cycle injection and (b) single cycle 
kinetic titration (Adapted with permission from ref. [114]. 
 
Multi-cycle injection procedure consists in a series of analyte dilutions 
delivered over the functionalized surface in a separate mode, with each interaction 
cycle recorded separately. Subsequently, sensorgrams produced by the different 
concentrations are aligned at the injection start event, overlaid and displayed 
together in the same graph. For slow dissociating complex is necessary to 
introduce a regeneration step at the end of the dissociation event to ensure that all 
binding sites on the surface are available for the next cycle. Otherwise, the partial 
occupation could interfere with the next analyte series, affecting the overall results. 
It is important to consider that the regeneration step must leave the functionality of 
the ligand unaltered in order to guarantee the reproducibility of the interaction 
among different cycles. 
 
Single-cycle injection: Sometimes the regeneration conditions are hard to 
optimize for the interaction monitored, because of the instability of the ligand on 
the surface or the intrinsic properties of the complex that is formed. An alternative 
approach has been developed to overcome these problems – the single-cycle 
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injection. It consists in a series of analyte dilutions delivered sequentially over the 
surface, without regeneration between injections. Data analysis software that takes 
into consideration the gradual occupation of binding sites during the run, allow 
accurate determination of kinetic and thermodynamic parameters. Moreover, 
tightly bound complexes, usually characterized by slow dissociation kinetics, are 
easy to analyze since the time required for a complete experiment decrease 
significantly and hard regeneration conditions can be avoided. 
 
5.4. Data evaluation 
Different aspects of the (bio)molecular interaction can be studied depending on 
the final goal of the analysis, the quality of the data and the intrinsic behavior of 
the two binding partners113, 115-117. Since the amplitude of the SPR signal is directly 
correlated to the change in mass at the sensor surface, the molecular weights of the 
chemical species involved impose a limitation on the maximal theoretical response 
achievable for the system under investigation. Comparison of the maximal 
theoretical and experimental responses can provide information on the apparent 
binding capacity (often termed the “activity”) of the immobilized ligand and on the 
stoichiometry of the interaction according to the equation (3): 
 Rmax = MWanalyte / MWligand ⋅ RUimmobilized ⋅ n   (3) 
where Rmax is maximal response of the system, MWanalyte and MWligand the 
molecular weight of the analyte and ligand respectively, RUimmobilized is the amount 
of ligand tethered to the surface and n the stoichiometry of the analyte–ligand 
reaction. 
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Plotting responses at steady state against the injected concentrations results in a 
classical dose-response curve118 (Fig. 16). The steady state affinity (KD) for the 
analyte–ligand complex can be estimated by non-linear regression analysis of the 
data set according to the following equation (4): 
 
 
R = Rmax i ⋅( C / KDi )1+C / KDii
∑   (4) 
where C is the analyte concentration, and KD is the equilibrium dissociation 
constant. For a single-site interaction, i = 1, and for multiple binding sites i = n, 
where n is the stoichiometry of the reaction imposed by the number of available 
binding sites.  
Time required to reach the equilibrium for a given reaction is mostly dependent 
on the dissociation rate koff of the complex; therefore, is not always possible to 
achieve a steady state condition during the length of an injection, especially at low 
compound concentrations. However, since responses at equilibrium are not 
affected by rate of diffusion and they do not account for complex and ambiguous 
reaction profiles, this approach can sometimes overcome intrinsic limitations of a 
kinetic fitting procedure98. The interaction between serum albumins (SA) and 
cucurbitacins benefited from steady state affinity analysis rather than kinetic 
evaluation (see chapter 6). The fast nature of the binding event hampered the 
quantification of rate constants, providing however a qualitative estimation. 
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Figure 16 | Representative sensorgrams showing typical Warfarin/HSA interaction over a 
wide range of concentrations. (a) Overlaid sensorgrams obtained from replicate injections of 
warfarin (0.2 – 400 μM) over HSA-functionalized surface. (Inset) Responses collected from the 
reference surface. (b) Response at equilibrium plotted versus warfarin concentration. The solid line 
depicts the fit of the data to a theoretic model describing two independent-sites reaction, while the 
dashed line represents the saturation point of the high-affinity site. The fit yields equilibrium 
dissociation constants of 3.8 and 273 μM for the high-and low-affinity sites, respectively. 
Reprinted with permission from reference [118]. 
 
Global non-linear regression analysis of a set of sensorgrams at different 
analyte concentrations can be used to estimate the rate constants for association 
(kon) and dissociation (koff) events. Computational methods are used to fit theoretic 
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binding modes to the experimental data and statistical tools are employed to assess 
their consistency. Some of the most common binding modes are reported here:  
 a) 1:1 binding (eq. 5): 
 
A+ B
kon
koff
! ⇀!!!↽ !!!! AB  (5) 
with an overall rate equation for the forward and backward reaction represented by 
Eq. 5.1: 
 
d [ AB ]
dt
= kon ⋅ [ A] ⋅ [ B ] − koff [ AB ]  (5.1) 
and an equilibrium dissociation constant describes by Eq. 5.2: 
 
KD = koff kon   (5.2) 
where kon is the association rate constant (M−1 s−1) and koff is the dissociation rate 
constant (s−1). 
b) Heterogeneous binding, with two independent reactions occurring in parallel 
(eq. 6): 
 
A+ B1
kon1
koff1
! ⇀!!!↽ !!!! AB1
A+ B2
kon2
koff2
! ⇀!!!↽ !!!! AB2
  (6) 
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that can be described as the sum of two independent reactions occurring in 
parallel, each one of them described by a simple 1:1 mechanism with its associated 
rate equations. This model yields two different sets of kon and koff and two different 
values of KD. 
c) Two-step reaction, which entails a conformation rearrangement after the first 
initial encounter between the two interactants, leading to a more stable 
conformation (eq. 7): 
 
A+ B
kon1
koff1
! ⇀!!!↽ !!!! AB
kon2
koff2
! ⇀!!!↽ !!!! AB*  (7) 
The rate equations for the two reactions are described by Eq. 7.1 and Eq. 7.2: 
 
d [ AB ]
dt
= ( kon1 ⋅ [ A] ⋅ [ B ] − koff1 ⋅ [ AB ])− ( kon2 [ AB ] − koff2 ⋅ [ AB* ])  (7.1) 
 
d [ AB* ]
dt
= ( kon2 ⋅ [ AB ] − koff2 ⋅ [ AB* ])  (7.2) 
with an associated equilibrium dissociation constant, that needs to take into 
account both reactions, described by Eq. 7.3: 
 
KD =
koff1
kon1
⋅ koff2
koff2 + kon2
 (7.3) 
where kon1 (M−1 s−1) and koff1 (s−1) are the association rate constant and the 
dissociation rate constant for the first biding event, and kon2 (s−1) and koff2 (s−1) 
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represent the kinetic rate constants for the switching to a more stable AB* 
complex. 
Statistical tool χ2 describes the dispersion of experimental data around the 
theoretic interaction and as a rule of thumb is should be less than 10% of the Rmax 
for a reliable fit. Residual plots are a graphical image of the χ2, and by visually 
inspecting them systematic deviations can be recognized and the accuracy of the 
fitting procedure graded. 
Whenever kinetic information on biorecognition events wants to be acquired a 
high degree of precision in the experimental design is compulsory. To get reliable 
data from the fitting procedure is essential to assess behavior of the system under 
investigation: all interactions have to be strictly related to analyte–ligand binding 
events and avoid artifacts arising from unspecific adsorption to the surface, mass 
transport limitations or rebinding effects. 
Unspecific binding to the surface is mostly related to precipitation of the 
analyte during the injection, or to the intrinsic charge-dependent interaction with 
the slightly acidic carboxymethyl dextran layer of the chip. Mass transport 
limitation (MTL) occurs when the diffusion of the analyte from the bulk solution 
to the immediate proximity of the surface, where it can bind the ligand, is too slow 
with respect to the association event (kon). In this instance, diffusion will be the 
limiting step for the complex formation rather than on-rate. MTL regard mostly 
protein–protein interactions; macromolecules have limited diffusion rates 
compared to small molecules for which this factor is usually negligible. In the 
present dissertation an extensive assessment of the MTL contribution to the 
interaction between transcription factor HpNikR and dsDNA sequence OPureA was 
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conducted and all the experimental details used to minimizing it are presented 
(chapter 7).  
Although there are several fitting models available, which also accounts for 
artifacts-related deviations, choice of which apply should be carefully evaluated 
and if otherwise suggested should be kept as simple as possible, i.e. 1:1 reversible 
binding.  
An extended experimental set-up can improve comprehensions for mechanisms 
deviating from a classical 1:1 binding event and discern them in real multi-
components interactions mechanism or poorly designed experiments119-121. In the 
present dissertation an extended experimental procedure was employed to 
characterize the interaction between the HpNikR and OPureA where shape of 
sensorgrams shed light was indicative of a two-step binding mechanism rather than 
heterogeneous binding to the surface (chapter 7)16. 
Overall, kinetic analysis can provide valuable information that otherwise will 
be lost by the measurement of a simple condition of equilibrium. The possibility to 
distinguish general affinity into its individual components (KD = koff / kon), provide 
an important tool to construct more complete structure-activity relationship. 
Synthesis can be conducted to enhance desired futures with more accuracy, for 
example: a tight binder with a slow koff will ensure longer residence time (τ) over 
its receptor and therefore will lengthen its effect while possibly reducing its off-
target toxicity50. Moreover, multi-component sensorgrams can be deconvoluted 
into their individual components giving an insight in biorecognition events 
endowed with exclusive conformational rearrangements. 
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Abstract 
Cucurbitacins are a group of tetracyclic triterpenoids, known for centuries for their 
anticancer and antiinflammatory properties, which are being actively investigated 
over the past decades in order to elucidate their mechanism of action. In 
perspective of being used as therapeutic molecules, an early pharmacokinetic 
characterization is highly desirable. Usually, pharmacokinetic data are first 
collected on animal models and later translated to humans; therefore, an in vitro 
characterization of the interaction with carrier proteins from different species can 
help forecast distribution volumes in the two different hosts. In the present study, 
the interactions of cucurbitacins E and I with human and rat serum albumins (HSA 
and RSA) were investigated by means of surface plasmon resonance (SPR)-based 
optical biosensing and circular dichroism (CD) spectroscopy. Active HSA and 
RSA sensor chip surfaces were prepared through an amine coupling 
immobilization protocol, and the equilibrium dissociation constants (KD) for the 
different cucurbitacins-serum albumins complexes were then determined by SPR 
analysis. Further information on the binding of cucurbitacins to serum albumins 
was obtained by CD competition experiments with biliverdin, a specific marker 
binding to subdomain IB of HSA. SPR data unveiled a previously unreported 
binding event between CucI and HSA; the determined binding affinities of both 
compounds were slightly higher for RSA with respect to HSA, even though all the 
compounds can be ranked as high-affinity binders for both carriers. CD analysis 
showed that the two cucurbitacins modify the binding of biliverdin to serum 
albumins through opposite allosteric modulation (positive for HSA, negative for 
RSA), confirming the need for caution in the translation of pharmacokinetic data 
across species. 
 67  
Introduction 
Cucurbitacins (Cuc) are a class of highly oxygenated, tetracyclic triterpenoids 
primarily isolated from the plant family of Cucurbitacee. The cytotoxicity of 
cucurbitacins has been known for centuries and the elucidation of their mechanism 
of action is an active topic of research; several biological and pharmacological 
activities have been reported, proposing cucurbitacins as potential anti-cancer, 
anti-inflammatory and anti-microbial agents122-125. For instance, cucurbitacin E 
(CucE, Fig. 17) disrupts the F-actin cytoskeleton, inhibiting the growth of human 
prostate carcinoma PC-3 cells126, and displays anti-angiogenesis activity in human 
umbilical vascular endothelial cells by suppressing the VEGFR2-mediated Jak2–
STAT3 signaling pathway127; cucurbitacin I (CucI, Fig. 17), the deacetylated form 
of CucE, induces apoptosis in Sézary syndrome cells through the inhibition of the 
same pathway128 and displays cardioprotective properties through the suppression 
of the tissue growth factor-mediated signaling pathways in hypertrophic 
cardiomyocytes129. 
 
 
Figure 17 | Chemical structure of CucE and CucI. 
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In view of the potential use of cucurbitacins as therapeutic agents, binding 
studies with carrier proteins, and in particular with serum albumins, are highly 
desirable in order to better characterize their distribution and bioavailability for 
their primary targets, and therefore understand their pharmacological behavior. 
Human serum albumin (HSA) is the most abundant protein carrier in blood 
serum130 HSA possesses the ability to bind to several different classes of 
compounds, both endogenous and exogenous, modulating their properties such as 
solubility, availability, toxicity and stability130. Several techniques have been 
successfully applied to characterize the binding properties of HSA, e.g. 
equilibrium dialysis, high-performance affinity chromatography and fluorescence 
spectroscopy to name a few20, 131-135. Among these, circular dichroism (CD)33, 136 
spectroscopy offers the analytical advantages given by its trademark sensitivity to 
chirality, allowing the investigation of binding events through the phenomenon of 
induced circular dichroism (ICD)91. The ICD signals of specific high-affinity 
markers for the binding sites of HSA can therefore be exploited to characterize the 
binding of other analytes by means of competition studies in solution66, 137. 
Optical biosensors based on surface plasmon resonance (SPR) have also been 
employed during the last years in order to study the interaction between small 
molecules and proteins138-141. In a typical SPR experiment, one of the two binding 
partners is chemically attached to the surface of a sensor chip (ligand), while the 
other is free to flow in solution (analyte) and is thus able to interact with the 
ligand. The response (R), given in arbitrary resonance units (RU), is dependent on 
the refractive index of the chip surface, which varies proportionally to the change 
in mass due to the association and/or dissociation of the binding complex between 
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ligand and analyte. This technique offers advantages over the conventional 
solution-based techniques:  
(a) The interaction between two molecules can be monitored without the need 
of any labeling, obtaining binding information about unmodified reactants and 
avoiding the possibility to alter the binding properties142.  
(b) Sensor chips can be used for several cycles of analysis without 
compromising their functionality, therefore increasing the throughput of the 
technique49.  
(c) Unlike other equilibrium-based techniques, the interaction can be monitored 
in real time, providing more detailed information about the binding process143.  
The latter feature is of particular interest when monitoring biological systems, 
especially when dealing with carrier proteins, since the kinetics of binding greatly 
influences the pharmacokinetic properties of the bound molecules118.  
During pre-clinical and clinical trials, animal models are routinely used to test 
the binding properties and the consequent bloodstream distribution of new drug 
candidates in order to extrapolate pharmacokinetic data for the human body144. 
Though HSA and rat serum albumin (RSA) share a high degree of homology in 
their amino acid sequences, differences in their binding properties has already 
been known for long time145. Therefore, the investigation of the binding 
differences among serum albumins from different species becomes of great 
importance before extrapolating data for clinical studies in humans. Exploiting the 
versatility of the experimental setup given by SPR-based biosensors, evaluations 
on the binding properties of different compounds toward immobilized serum 
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albumins from different species can be achieved and compared with data obtained 
from other solution-based affinity techniques. 
 In the present study, cucurbitacins–serum albumins (Cuc–SA) binding 
complexes were investigated by means of a combination of SPR-based optical 
biosensing and CD spectroscopic analysis, with particular focus on the binding of 
CucE and CucI with HSA and RSA. 
 
Results and discussion 
 SPR analysis of Cuc–SA interactions 
Serum albumins’ surfaces preparation and validation 
High-efficient immobilization was achieved through amine coupling chemistry. 
With this procedure HSA is tethered to the dextran coating through its primary 
amine groups exposed to the surface, i.e. lysine residues, and previous studies have 
already reported that all major binding sites are readily available and accessible in 
these conditions118, 146. 
Prior to the immobilization, a pH scouting procedure was performed in order to 
determine which solution, gave the most stable interactions between the ligand and 
the chip surface. At pH 5.0, HSA produces a stable and time-dependent 
interaction, which was optimal to control the immobilization density by setting the 
adequate injection time at the beginning of the procedure. To confirm the full 
functionality of produced chip surfaces, naproxen (marker for the Sudlow site II of 
HSA)131, 132 and (S)-warfarin (Sudlow site I marker) were used as standard 
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compounds to assess their affinity toward the HSA surfaces. In all cases, a good 
concentration–response relationship was observed and the resulting KD values (3.6 
· 10−5 M for naproxen and 6.0 · 10−6 M for (S)-warfarin on the high-density chip 
surface; 2.5 · 10−5 M for naproxen and 3.6 · 10−6 M for (S)-warfarin on the low-
density chip surface) were in accordance with previously reported SPR analyses 
(KD values in the range 3.0 · 10−6 to 2.6 · 10−5 M for naproxen, 3.7 · 10−6 to 1.4 · 
10−5 M for (S)-warfarin)118, 146. The affinity of (S)-warfarin toward the RSA 
surface was also assessed, yielding a KD value of 2.3 · 10−5 M which is in good 
agreement with literature data147. 
Affinity of Cuc–SA complexes 
All interactions reached a steady state condition within few seconds from the 
analyte injection and all complexes dissociated rapidly as indicated from the 
square wave shape of the sensorgrams (Fig. 18). Binding events between HSA and 
Cuc were tested over two sensing surfaces. Reproducing biosensor data on 
different preparations gives more reliability to the whole analysis by avoiding 
surface-dependent artifacts. 
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Figure 18 | Representative SPR sensorgrams (top) and Req values fitted to the 1:1 isotherm 
binding model (bottom) for CucE and CucI binding to the high-density HSA and RSA chip 
surfaces. Increasing concentrations of analyte are denoted by different shades of green (from light 
to dark): 0.05, 0.09, 0.18, 0.35, 0.70, 1.40 and 2.80 µM for CucE–HSA; 0.04, 0.08, 0.17, 0.34, 
0.68, 1.35 and 2.70 µM for CucI–HSA; 0.05, 0.09, 0.18, 0.35, 0.70, 1.40 and 2.80 µM for CucE–
RSA; 0.04, 0.08, 0.17, 0.34, 0.68, 1.35 and 2.70 µM for CucI–RSA. 
 
Second surface was prepared with reduced HSA immobilization level. In this 
condition, the Rmax signals decreases and the signal-to-noise ratio decreases 
accordingly; however, the influence of non-specific interactions, such as steric 
hindrance, crowding and aggregation at the functionalized surface, is also reduced 
allowing to provide cleaner and more reliable sensorgrams113. The binding affinity 
of the CucE–HSA interaction, was determined by independent experiments on 
both sensor chips, and resulted in an average KD value of 5.0 · 10−7 M, which is in 
good agreement with the literature value of 5.8 · 10−7 M obtained by solution-
based fluorimetry assays148. 
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The KD value for the binding of CucI toward HSA was estimated to be 1.8 · 
10−6 M, suggesting a previously unreported interaction between the two molecules. 
On the other hand, both CucE and CucI showed higher affinity toward RSA with 
respect to HSA, with estimated KD values of 2.9 · 10−7 M and 2.8 · 10−7 M, 
respectively.  
The binding percentage of cucurbitacins to serum albumins (expressed as the 
percent fraction of bound drug, xb) was also estimated. The xb values were derived 
from KD following the procedure described by Rich et al.118, assuming a 
physiological serum albumin concentration of 680 µM and a Cuc concentration of 
10 µM, which is the standard concentration used in the majority of dialysis studies 
reported in literature. The corresponding xb values indicate that both cucurbitacins 
can be ranked as high-affinity binders for HSA and RSA. Results for all the 
analyzed interactions are reported in Table 2. 
 Kd (M) kon (M−1 s−1) koff (s−1) koff / kon (M) xb (%) 
CucE–HSA (5.0 ± 1.0) · 10−7 (3.6 ± 0.7) · 105 (3.4 ± 0.7) · 10−1 a (9.5 ± 1.1) · 10−7 99.3 ± 0.1 
CucE–RSA (2.9 ± 1.0) · 10−7 – b – b – b 99.6 ± 0.1 
CucI–HSA (1.8 ± 0.7) · 10−6 (4.6 ± 2.4) · 104 (1.5 ± 1.2) · 10−1 a (3.4 ± 1.5) · 10−6 97.4 ± 1.0 
CucI–RSA (2.8 ± 0.1) · 10−7 – b – b – b 99.6 ± 0.1 
 
Table 2 | Equilibrium dissociation constant (KD), kinetic rate constants (kon and koff) and 
percentages of binding (xb) derived from the SPR analysis on Cuc–SA binding complexes. 
 
The kinetics of binding between cucurbitacins and HSA was then evaluated by 
applying a 1:1 kinetic interaction model (eq. 5) to the SPR datasets, in order to 
extrapolate the kon and koff rate constants (Fig 19). 
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Figure 19 | Kinetic fitting of SPR sensorgrams for CucE and CucI binding to the high-density 
HSA chip surface. Increasing concentrations of analyte are denoted by different shades of green 
(from light to dark): 0.04, 0.18, 0.70 and 2.80 µM for CucE; 0.04, 0.17, 0.68 and 2.70 µM for CucI. 
 
The residual plots and the χ2 values were examined to assess the reliability of 
the theoretical model applied to the experimental data; full details are reported in 
the Supplementary Material of original manuscript. The KD values derived from 
equation 5.2 for the Cuc–HSA interactions (9.5 · 10−7 M for CucE, 3.4 · 10−6 M 
for CucI) were similar to the ones obtained from the steady-state affinity study; on 
the other hand, the model failed to provide reliable values for the kinetic 
parameters of Cuc–RSA interactions. The determined kinetic rate constants allow 
to hypothesize that part of the higher affinity toward HSA displayed by CucE with 
respect to CucI is due to a 8-fold faster association (kon= 3.6 × 105 M−1 s−1 for 
CucE, kon = 5.0 ×104 M−1 s−1 for CucI), although the BIAcore evaluation software 
provided numerical estimates for the koff rate constants which are often outside the 
optimal range of work of the instrument in the Supplementary Material of the 
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original article. As a consequence, the fast nature of this specific dissociation event 
may require further examination and more advanced techniques to be measured 
with greater precision. 
CD analysis of Cuc–SA interactions 
The cucurbitane skeleton of CucE and CucI (Fig. 17) is characterized by the 
presence of 8 stereogenic centers of defined absolute configuration at positions 8 
(S), 9 (R), 10 (R), 13 (R), 14 (S), 16 (R), 17 (R) and 20 (R). CucE only differs 
from CucI for the presence of the acetoxy group in place of the hydroxy group at 
position 25, which is however too distant from the stereogenic centers to be 
affected by the overall stereochemistry and to display a strong contribution to the 
chiroptical properties of CucE. The observation of very similar CD signals for 
CucE and CucI is therefore not surprising (Fig. 20): the spectra in the 450–250 nm 
spectral range are dominated by the n → n* of the three ketone chromophores and 
by the σ → σ* transitions of the two unsaturated ketones, which give rise 
respectively to a negative CD band centered at 327 nm and a positive CD band 
centered at 282 nm. 
The n→ n* CD band of CucE and CucI lies in a spectral region where the 
spectroscopic contribution of serum albumins is absent, which is an ideal situation 
for monitoring eventual ICD phenomena. Upon binding to serum albumins, 
however, the CD profiles of CucE and CucI are not altered, meaning that the 
binding mechanism is not endowed with a particular stereospecific character (Fig. 
20). 
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Figure 20 | CD and UV spectra of CucE and CucI in solution (solid lines) and protein-corrected 
spectra of their 2:1 complexes with HSA (dotted lines). Experimental conditions are reported in the 
Materials and Methods section. 
 
The position of the CD bands of CucE and CucI is also a huge limitation for the 
application of CD spectroscopy to the study of Cuc–SA complexes: the usual ICD 
markers for high-affinity HSA binding (phenylbutazone for the Sudlow site I in 
subdomain IIA, diazepam for the Sudlow site II in subdomain IIIA)66, 149 display 
their characteristic spectral features between 350 and 250nm. Therefore, 
competition studies by CD spectroscopy were performed using BV, an ICD 
marker for the proposed binding site III in subdomain IB of HSA150. 
Upon binding to HSA, the bound conformation of BV displays (M)-axial 
chirality with the onset of a negative ICD band centered around 670 nm and a 
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positive ICD band at 385 nm, both outside the spectral range of Cuc absorption 
(Fig. 21). BV also binds to RSA in (M)-conformation: the resulting positive ICD 
band for the 1:1 RSA–BV complex lies at the same wavelength as for the 1:1 
HSA–BV complex and is relatively more intense (∼+50%). 
 
Figure 21 | Protein-corrected CD and UV spectra for the 1:1 HSA–BV binding complex, in the 
absence (light green) and in the presence of cucurbitacins. Increasing concentrations of 
cucurbitacins are denoted by different shades of green (from light to dark). Experimental details are 
given in the Materials and Methods section in the supplementary of the original article.  
 
When CucE and CucI are added to the 1:1 HSA–BV complex, the magnitude of 
the ICD band for BV at 385 nm slightly increases (Fig. 22): interestingly, the 
enhancement of the ICD band is more pronounced when CucI is used in the 
competition study, while the effect of CucE is more limited. 
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Figure 22 | Effect of increasing concentrations of CucE (circles) and CucI (squares) on the 
magnitude of the positive ICD band of HSA–BV (solid lines) and RSA–BV (dotted lines) 
complexes. Experimental details are reported in the Materials and Methods section and in Tables 
S3–S4 in the Supporting Information. 
 
An increase in ICD intensity for a marker is usually indicative of positive 
allosteric modulation toward the binding site of the marker and an indirect proof of 
binding for the analyte. Previous investigations on Cuc binding to HSA by 
fluorescence spectroscopy revealed that CucE enhanced the affinity of bilirubin 
(BR) toward HSA, while CucI was found to have no effect on HSA–BR 
binding151. BR, the reduced form of BV, binds to the same subdomain IB of HSA 
and is also, incidentally, one of the most studied ICD markers for high-affinity 
HSA binding66, 149. The different effect of CucI on the binding of BR and BV to 
HSA may seem contrasting. It must be noted, however, that the additional 
flexibility of the reduced methylene bridge allows for a different binding mode of 
BR when compared to BV, even though both molecules bind to the same site of 
HSA; actually, the different signs of the corresponding ICD bands indicate that the 
stereoselectivity of binding for BR and BV is opposite, with BR binding to HSA 
 79  
with a (P)-axial chirality. In some cases, the axial chirality of bound BR can even 
be inverted through allosteric modulation152. The behavior of CucI confirms the 
high flexibility of the binding site in subdomain IB and the complex allosteric 
network regulating the binding of drugs to HSA. 
Interestingly, the positive ICD band for BV at 385 nm decreased in intensity 
when CucE and CucI were added to the 1:1 RSA–BV complex (Fig. 22), 
suggesting either a competition for the same binding site or a negative allosteric 
modulation. The available data are not sufficient to discriminate between these two 
different mechanisms, although the limited extent to which the ICD band for BV is 
decreased supports the hypothesis of negative allosteric modulation. It is worth 
noting that the binding of CucE and CucI to serum albumins of different species 
led to different effects on BV binding, confirming the need for careful 
investigations before translating pharmacokinetic profiles from animal models to 
humans. 
 
Conclusions 
The present article reported the investigation on the binding of cucurbitacins E 
and I to human and rat serum albumins by means of a combination of SPR-based 
optical biosensing and CD spectroscopic analysis. The steady state and kinetic 
analysis of SPR sensorgrams for Cuc–SA complexes unveiled a previously 
unreported binding event between CucI and HSA, with CucI showing a 3-fold 
lower affinity than CucE. Moreover, the KD values of CucE and CucI toward RSA 
resulted to be slightly higher than those observed for HSA, with both compounds 
binding to RSA with comparable affinity. The calculated percentages of binding 
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allow to rank cucurbitacins E and I as high-affinity binders for both serum 
albumins. CD spectroscopic analysis showed that cucurbitacins E and I are able to 
modulate the binding of biliverdin to serum albumins, as observed by the 
concentration-dependent change in intensity of the positive ICD band of biliverdin 
upon titration with cucurbitacins. Interestingly, the opposite behaviors observed 
with HSA and RSA suggest a different type of allosteric modulation by 
cucurbitacins, positive for HSA and negative for RSA. These observations allow to 
confirm the usefulness of SPR and CD analysis for the characterization of the 
pharmacokinetic profiles of drugs and the need for caution in the translation of 
pharmacokinetic data across species for new drug candidates. 
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Materials and methods 
 
Materials 
Cucurbitacin E (CucE; molecular weight, MW: 556.76 Da) and cucurbitacin I (CucI; MW: 514.16 
Da) were purchased from Extrasynthese (Genay, France). HSA (essentially fatty acid free, ≥96%, 
product code A1887; MW: 66.4 kDa), RSA (essentially fatty acid free, essentially globulin free, 
≥99%, product code A6414; MW: 64.6 kDa), sodium dihydrogen phosphate (NaH2PO4), disodium 
hydrogen phosphate (Na2HPO4), dimethyl sulfoxide (DMSO), sodium naproxen (MW: 252.24 Da), 
(S)-warfarin (MW: 308.33), biliverdin hydrochloride (BV; MW: 619.12 Da), sodium chloride 
(NaCl) and sodium acetate were all purchased from Sigma–Aldrich (Milan, Italy). Research-grade 
CM 5 sensor chips, 10X phosphate buffer saline (PBS) and the amine coupling kit, consisting in N-
ethyl-N-(3-dimethylaminopropyl)-carbodiimide (EDC), N- hydroxysuccinimide (NHS) and 
ethanolamine hydrochloride (pH 8.5; 1M), were all purchased from GE Healthcare Bio-Sciences 
(Uppsala, Sweden). Water was bi-distillated, de-ionized, filtered and degassed by Millipore Elix 
10. Phosphate buffer (PB) (20 mM) + NaCl (150 mM) (pH 7.4) (running buffer A) was used for the 
immobilization pro- cedure, while 1X PBS–DMSO (95:5, v/v) (pH* 7.4) (running buffer B) was 
used for the Cuc–SA interaction studies. All buffer solutions were freshly prepared prior to the 
analysis and filtered through a 0.22 µm pore size membrane made of a mixture of cellulose nitrate 
and acetate. 
 
SPR analysis 
Instrumentation 
SPR measurements were performed with a BIAcore X100 system (GE Healthcare Bio-Sciences, 
Uppsala, Sweden) equipped with an in-line degasser and thermostated at 25 ◦ C. Data were 
analyzed and processed using the BIAcore X100 2.0 evaluation software. 
 
Surface preparation and validation 
Stock solutions of HSA at a 30 g mL−1 concentration were prepared in sodium acetate buffers (10 
mM) at various pH values (pH 4.0, 4.5, 5.0 and 5.5), and the electrostatic pre-concentration at the 
chip surface was evaluated by injecting each stock solution for 180 s at a 5 µL min−1 flow rate, 
after which the baseline was re-established by injecting a NaOH solution (50 mM). The best 
condition was achieved using the pH 5.0 stock solution. 
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Consequently, HSA was immobilized on two CM 5 sensor chips via amine coupling according to 
the standard BIAcore procedure, using the pH 5.0 stock solution. Briefly, the chips were 
equilibrated at room temperature for 30 min before docking, and the system was primed three 
consecutive times with running buffer A. The carboxymethyl dextran matrix was activated on both 
channels of the sensor chip by injecting a freshly prepared mixture of EDC (0.4 M) – NHS (0.1 M) 
(1:1, v/v) at a 5 µL min−1 flow rate for 7 min. Then, the pH 5.0 stock solution of HSA was injected 
over the active flow cell until the desired amount of immobilized protein was reached, i.e. 9000 RU 
for the first sensor chip (hereafter referred to as high-density chip) and 5000 RU for the second 
(low-density chip), while running buffer A was injected over the reference flow cell in order to 
create a surface to account for non-specific binding events. Finally, the remaining active esters 
were quenched by injecting ethanolamine hydrochloride for 7 min at a 5 µL min−1 flow rate (Fig. 
S1 in the Supplementary Material of the original article). At the end of the whole procedure, the 
surfaces were allowed to stabilize overnight and, after several buffer injections, a steady baseline 
was achieved. A single RSA surface was prepared following the same protocol and resulted in an 
immobilization level of around 8500 RU. 
The affinities of naproxen toward HSA and (S)-warfarin toward HSA and RSA were evaluated in 
order to confirm the correctness of the immobilization procedure and validate the binding capacity 
of the chip surfaces. 1 mg mL−1 stock solutions of (S)-warfarin and naproxen in DMSO were 
diluted 1:20 (v/v) using 1X PBS to a final concentration of 162 µM and 198 µM, respectively, in 
running buffer B (pH* 7.4). These solutions were further diluted using running buffer B and 
injected over the surface at a 30 µL min−1 flow rate; association was allowed for 60 s and 
dissociation was monitored for 120 s. 
 
Solvent refractive index correction 
Since DMSO has a high refractive index (addition of 1% DMSO gives a bulk response of around 
1200 RU), a solvent correction procedure146 was performed to account for the small variations of 
DMSO percentage between samples and in the preparation of running buffers. Eight running 
buffers, consisting of 1X PBS mixed with different amounts of DMSO ranging from 4.5% to 5.8% 
(v/v) (pH* 7.4), were injected over the active and reference flow cells and a calibration curve was 
obtained. This procedure is very important while working with small molecules–macromolecules 
interactions, especially when the ligand is immobilized at high density (5000 RU or more). In this 
experimental set-up, the expected response has the same magnitude as, or lower magnitude than, 
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the signal arising from refractive index mismatches, therefore including a cor- rection protocol 
during the evaluation of the data becomes of great significance. 
 
Sample preparation 
2 mg mL−1 stock solutions of CucE and CucI were prepared in DMSO and stored at −20 ◦ C. The 
stock solutions were then diluted 1:20 (v/v) each day immediately before analysis using 1X PBS, 
resulting into a final concentration of 50 µg mL−1 in running buffer B (pH* 7.4) for both 
cucurbitacins. All further dilutions were made using freshly prepared running buffer B. 
 
Analysis of Cuc–SA interactions 
Affinity assays were carried out during the same day for both cucurbitacins at 25 ◦ C. The flow rate 
was set at 30 µL min−1 and kept constant throughout all the analyses. For the high-density HSA 
chip and for the RSA chip, association and dissociation were monitored for 60 s and 120 s, 
respectively, after which additional 300 s of running buffer B (pH* 7.4) were flowed. Every three 
cycles, a blank injection was performed in order to monitor the baseline stability and account for 
systematic and random variations. A concentration range from 3.0 µM to 0.04 µM, obtained by a 
series of two-fold dilutions, was used in order to assess the affinity of CucE and CucI for both 
serum albumins. 
Data for the Cuc–HSA interactions were also collected onto the low-density HSA chip surface, 
using a concentration range from 9.0 µM to 0.05 µM in a series of four-fold dilutions. Association 
and dissociation were both monitored for 30 s; subsequently, 120 s of running buffer B (pH* 7.4) 
were flowed over the surface in order to monitor the stability of the baseline. 
 
Data analysis 
Sensorgram datasets for CucE, CucI, naproxen and (S)-warfarin binding to serum albumins were 
processed according to the same protocol. The responses from the active flow cell were double- 
referenced against the responses from the reference flow cell and against an average of all the blank 
injections taken every three cycles of analysis; finally, the solvent refractive index correction was 
applied113. 
The resulting responses at equilibrium were fitted to a 1:1 isotherm binding model, defined in Eq. 
(4), in order to extrapolate the equilibrium dissociation constant (KD) of the ligand-analyte 
complex. 
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Each measurement was replicated at least twice and each dataset was fitted in the binding model 
independently; the resulting parameters were subsequently averaged and expressed with the 
corresponding standard deviation. Sensorgrams resulting from the Cuc–HSA interaction were also 
fitted to a simple 1:1 kinetic interaction model, according to which the KD value is derived from the 
ratio between the rate constants for association (kon) and dissociation (koff), as shown in Eq. 5.2. The 
χ2 parameter was used as a statistical tool to evaluate the closeness of the fitting model to the 
experimental data. The experimental datasets showing non-negligible residual plots after the 
statistical fitting were discarded and not taken into account for the determination of the kinetic 
constants. 
 
CD analysis 
Instrumentation 
CD and UV spectroscopic analyses were carried out at 25◦C on a Jasco (Tokyo, Japan) J-810 
spectropolarimeter equipped with a PTC-423S Peltier-type temperature control system, using a 10 
mm pathlength quartz cell (Hellma, Milan, Italy), a 2 nm spectral bandwidth, a 0.5 nm data pitch 
and an accumulation cycle of 3 runs per measurement. Data were analyzed and processed using the 
Jasco Spectra Manager 2 software package. 
 
Analysis of Cuc–SA complexes 
5 mM stock solutions of CucE and CucI were prepared in DMSO, while stock solutions of HSA 
(300 µM), RSA (300 µM) and BV (3 mM) were prepared in running buffer B (pH* 7.4). Samples 
of cucurbitacins (3.75, 7.5, 15, 30 and 60 µM) were prepared by directly diluting appropriate 
aliquots of 5 mM stock solutions with running buffer B (pH* 7.4). Cuc–SA complexes were 
analyzed at different drug/protein molar ratios (0.25, 0.5, 1, 2 and 4) by diluting the protein stock 
solution with running buffer B (pH* 7.4) to a concentration of 15 µM and subsequently adding 
increasing aliquots of Cuc stock solution. The resulting decrease in final protein concentration 
during all titration experiments never exceeded 1.5%, and the total content of DMSO in the 
samples never exceeded 6.5% (v/v). 
CD and UV spectra of samples were then measured in the 450–250 nm spectral range using a 50 
nm/min−1 scanning speed and a 2 s data integration time. The increase in DMSO content did not 
increase the solvent contribution to the total spectroscopic response of samples in the investigated 
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spectral range; consequently, solvent corrections for the samples of cucurbitacins were performed 
by subtracting the signal of running buffer B (pH* 7.4). On the other hand, the spectra of 
drug/protein samples were corrected by subtracting the spectra of serum albumins, in order to 
evaluate the eventual onset of ICD signals upon binding. 
 
Competition studies with biliverdin 
A similar protocol was used for competition experiments on HSA–biliverdin (BV) complexes (in 
the Supplementary Material of the original article): HSA and BV were mixed at a molar ratio of 1:1 
and diluted to 15 µM in running buffer B (pH* 7.4). Increasing aliquots of Cuc stock solution were 
subsequently added to the 1:1 HSA–BV complex in order to obtain different Cuc/SA molar ratios 
(0.5, 1, 1.5, 2, 3 and 5). 
For RSA–BV competition experiments (Fig. S5 in the Supplementary Material of the original 
article), the concentration of the 1:1 protein/marker complex was kept at 7.5 µM in running buffer 
B (pH* 7.4); subsequently, increasing aliquots of Cuc stock solution were added to the 1:1 RSA–
BV complex yielding different Cuc/SA molar ratios (0.33, 0.67, 1, 1.33, 2, 4 and 6). 
CD and UV measurements were carried out in the 700–250 nm spectral range using a 100 nm 
min−1 scanning speed and a 1 s data integration time; blank corrections were performed by 
subtracting the spectra of serum albumins from the spectra of protein/marker and 
drug/protein/marker samples. The effect of CucE and CucI on the ICD signal of BV was monitored 
at the wavelength of maximum UV absorption for BV, lying at around 385 nm: the relative 
variations of the corresponding ICD signal (expressed as percentage) with respect to the HSA–BV 
and RSA–BV complexes were plotted as a function of the Cuc/SA molar ratio (Tables S3–S4 in the 
Supplementary Material of the original article). 
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Abstract 
NikR is a transcription factor that regulates the expression of Ni(II)-dependent 
enzymes and other proteins involved in nickel trafficking. In the human 
pathogenic bacterium Helicobacter pylori, NikR (HpNikR) controls, among 
others, the expression of the Ni(II) enzyme urease by binding the double-strand 
DNA (dsDNA) operator region of the urease promoter (OPureA) in a Ni(II)-
dependent mode. This article describes the use of surface plasmon resonance 
(SPR) spectroscopy in combination with isothermal titration calorimetry (ITC) to 
carry out a mechanistic characterization of the HpNikR–OPureA interaction. An 
active surface was prepared by affinity capture of OPureA and validated for the 
recognition process in the SPR experiments. Subsequently, the Ni(II)-dependent 
affinity of the transcription factor for its operator region was assessed through 
kinetic evaluation of the binding process at variable Ni(II) concentrations. The 
kinetic data are consistent with a two-step binding mode involving an initial 
encounter between the two interactants, followed by a conformational 
rearrangement of the HpNikR–OPureA complex, leading to high affinity binding. 
This conformational change is only observed in the presence of the full set of four 
Ni(II) ions bound to the protein. Additionally, the SPR assay developed and 
validated in this study constitutes a suitable method to screen potential drug lead 
candidates acting as inhibitors of this protein–dsDNA interaction. 
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Introduction 
Ni(II) is an essential micronutrient for several bacteria, archea, plants, fungi, 
and unicellular eukaryotes153, 154. Its limited availability, coupled to its intrinsic 
toxicity, represents a pressure factor for the development of specific systems for 
metal accumulation, detoxification, and utilization, governed by Ni(II)-specific 
cellular responses. These processes are controlled by dedicated transcriptional 
regulators, whose ability to recognize or bind DNA is modulated in response to the 
Ni(II)-loaded state of the proteins, acting as fine sensors of intracellular Ni(II) 
concentration155. 
The most studied Ni(II)-sensor is NikR, a transcription factor that controls 
Ni(II) metabolism in more than 30 species of bacteria and archea. NikR from 
Helicobacter pylori (HpNikR) is a pleiotropic regulator156, 157: it represses its own 
gene as well as the gene coding for NixA, a Ni(II) permease responsible for the 
import of Ni(II), and acts as an activator of genes coding for the Ni(II)-dependent 
urease, a pathogenic factor158, 159. Crystal structures of HpNikR, Escherichia coli 
NikR (EcNikR) and Pyrococcus horikoshii NikR (PhNikR), established that this 
protein is a homo-tetramer, made of a dimer of dimers, constituted by two 
domains: the central metal-binding domain (MBD) and two ribbon-helix-ribbon 
DNA-binding domains (DBDs)160-166. MBD is constituted by dimerization of the 
C-terminal portion of the protein, it is responsible for tetramerization and hosts 
four regulatory Ni(II) binding sites; the DBDs are built from the dimerization of 
the N-terminal portion of the protein, they flank the MBD and are responsible for 
dsDNA binding. 
NikR has been observed in three different conformations in the crystal 
structures, open, trans, and cis, depending on the conformation of the short link 
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between the MDB and the DBDs. Notably, the cis conformation is adopted when 
the protein binds to dsDNA in the presence of Ni(II)163. 
In addition to structure-based design and development of new urease 
inhibitors167, the elaboration of new strategies against H. pylori could also entail 
the modulation of its Ni(II)-dependent transcriptional pathways by preventing the 
functional interaction of the Ni(II)-loaded HpNikR with its dsDNA operator. 
Protein binding to DNA generally involves large surfaces, and it is therefore more 
difficult to drug than deep binding pockets present in most enzymes. In addition, 
transcription factors such as NikR do not generally show enzymatic activity usable 
as a probe. For this reasons, protein–DNA interactions were previously defined as 
undruggable168. Nevertheless, some examples of small molecules (SMs) targeting 
these molecular recognition processes are emerging, especially in cancer 
research169. High-throughput screenings have been developed, rendering SM 
screening possible for this aim170, 171. 
In the last decades, optical-based surface plasmon resonance (SPR) biosensors 
have become more frequently employed at different stages of the drug discovery 
process because of their relative ease of use, versatility, small samples 
consumption, and short analysis time49, 172, 173. A typical SPR platform offers the 
possibility to perform real-time evaluation on unmodified interactants, without the 
need of a time-consuming labeling step, thus providing a valid tool to monitor a 
wide range of biological events, such as protein–protein interactions and small 
molecule–receptor interactions49. Furthermore, the real-time measurements allow a 
reliable determination of kinetic parameters, in addition to steady-state affinity and 
thermodynamic data174. If the technique is fully exploited and the SPR 
experiments are carefully designed, it is even possible to resolve multi components 
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reaction mechanisms, thus providing helpful aid to study complex binding 
events121, 175. Additionally, in-solution competition assays can be performed, 
taking advantage of the experimental set up versatility176. For instance, large 
molecules (e.g., proteins), which possess an intrinsically high SPR signal due to 
their mass, can compete with small molecules (e.g., therapeutic agents), which 
feature low SPR signal, for the same binding sites on the ligand; SPR responses 
are lowered considerably when SMs bind stronger than large molecules, providing 
a tool to rank inhibition capacity for selected compounds177, 178.  
Along with SPR, isothermal titration calorimetry (ITC) can be used to obtain 
thermodynamic information of intermolecular interactions, and thanks to its high 
sensitivity, ITC has become widely used to study biomolecular equilibria 
involving protein–ligand, protein–protein, protein–metal ions, and protein–DNA 
interactions179. In addition to thermodynamic parameters, kinetic information can 
also be extrapolated by means of ITC to study enzymatic reactions180, 181 as well as 
to provide complete kinetic characterization of biomolecular interactions182-184. 
In the present work, SPR spectroscopy is employed to derive kinetic and 
thermodynamic parameters of the HpNikR–OPureA system, in order to gain 
fundamental insights into the reaction mechanism and the role that Ni(II) plays in 
this protein–dsDNA binding process. A sensor chip surface bearing immobilized 
dsDNA OPureA was prepared by affinity-capture technique, and its functionality 
and recognition ability were extensively assessed. Auto-competition experiments 
were also performed, to further confirm the specificity of the recognition 
mechanism. These results were complemented and supported by ITC data. 
Moreover, the outcome of this study is the development of an assay for the 
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screening of potential lead candidates to target this interaction, paving the way 
toward rationally designed therapeutic agents. 
 
Results and discussion 
Surface plasmon resonance analysis 
Surface preparation and validation 
Biotinylated-OPureA was immobilized onto a streptavidin-functionalized 
sensor chip, ensuring a stable surface with an estimated functionality of 60 % (Eq. 
3). Interactions were reproducible over 100 analysis cycles, and no significant drift 
of the baseline was detected. 
The magnitude of the SPR signal is proportional to the molecular mass of the 
interactants according to equation 3, allowing high instrumental responses, up to 
1000 RU, for our system. Nevertheless we chose to keep the maximal response at 
100 RU, to reduce unspecific binding due to crowding effects. Therefore, 
streptavidin was covalently immobilized onto a CM5 sensor chip at approximately 
2000 RU, corresponding to a density level of 2 ng mm-2, and the OPureA operator 
sequence was captured over the streptavidin coated surface at a low level of 
approximately 30 RU. Capture of OPureA was performed at low flow rate, using 
diluted solutions, exploiting the affinity for the biotin residue on the DNA, as this 
procedure is known to generate an homogeneous surface, where ligand molecules 
posses a common orientation113, 185. Ten base pairs, corresponding to a full helix 
turn, were added to the operator sequence to better separate the double strand from 
the dextran layer, allowing HpNikR to bind the sequence without steric hindrance. 
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The shape of relative sensorgrams for association and dissociation events of the 
Ni(II)-HpNikR–OPureA complex are generally smooth and of high quality, without 
any apparent mass transport limitation (MTL) effect. However, during the 
optimization process, different sensor chips were prepared with different densities 
of both streptavidin and OPureA and the contribution of the MTL was extensively 
assessed onto the surface, which showed the best interaction profile (Fig. 23). 
Kinetic rate constants kon and koff for a given interaction are independent from the 
flow rate applied, therefore if the mass transport limitation (MTL) is negligible, 
their values should not change with the flow rate. Hence, fix concentration of 
analyte was injected at different flow rate, 20, 40 and 60 µL min−1 and the 
resulting experimental data were fitted to a 1:1 binding model; then all data were 
superimposed in the same plot (Fig. 23d). Both experimental and theoretical 
sensorgrams are overlapping, and their shapes are exponential from the first 
seconds of the association phase indicating that the MTL is not interfering with the 
reaction monitored. In addition, the mass transport coefficient kt being two orders 
of magnitude larger than the association rate constant kon, further indicates the low 
contribution of the MTL. Therefore an average flow rate of 30 µL min−1 was 
chosen as best the condition to minimize sample consumption. 
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Figure 23 | Different combination of streptavidin and biotinylated–OPureA were immobilized over 
the CM5 sensor chip surface. In the preparation (a) 4000 RU of streptavidin were covalently 
attached to the surface through amine coupling reaction and 75 RU of dsDNA were loaded over the 
surface. Ni(II)-HpNikR 500 nM was then injected at 30 µl min−1 flow rate. Similarly two different 
surfaces were prepared bearing (b) 4000 RU of streptavidin, 40 RU of dsDNA and c) 2000 RU of 
streptavidin, 30 RU of dsDNA, respectively, and the Ni(II) bound protein was injected at a 
concentration of 1 µM. Since the preparation (c) clearly showed the best interaction profile, the 
mass transport limitation (MTL) on the interaction was assessed with the injection of a fix Ni(II)-
HpNikR concentration (125 nM) at different flow rates 20, 40 and 60 µl min−1. Association and the 
dissociation were monitored for 90 and 120 seconds respectively and the relative sensorgrams were 
displayed in panel (d). The overlaying of the experimental data (black dots) and the theoretical 
fitting for the different flow rates analyzed in the study (20 µL min−1, red; 40 µL min−1, blue and 60 
µL min−1, green) along with the mass transport coefficient kt being two order of magnitude larger 
than the association rate constant kon (both obtained from the non-linear regression analysis), can be 
taken together as an indication of the small influence of the MTL on the interaction monitored. 
 
HpNikR–OPureA interaction analysis 
Since HpNikR in its simplest description is represented by a fully functional 
protein bound to four Ni(II) ions or by an inactive protein devoid of any bound 
Ni(II)186, the biological activity of the sensor chip was evaluated through the 
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injection of the protein in the absence or in the presence of four Ni(II) ions per 
tetramer (Fig. 24).  
 
Figure 24 | Double-referenced sensorgrams representing the interaction between the holo form of 
Ni(II)-HpNikR bound to four Ni(II) ions, (black lines) or the apo- form of HpNikR devoid of Ni(II) 
ions (light grey) with the OPureA tethered to sensor chip surface. Samples were injected in 
increasing protein concentrations. Ni(II)-HpNikR / apo-NikR (2, 10, 50, 250, 1000) nM 
 
The resulting sensorgrams showed that HpNikR does not bind the urease 
operator in the absence of Ni(II), while holo-HpNikR interacts with dsDNA in the 
presence of four Ni(II) equivalents per protein tetramer, confirming that OPureA has 
retained its functionality after the immobilization procedure. The specificity of the 
recognition process was also assessed by means of a competition assay: upon 
incubation of Ni(II)-HpNikR with equimolar concentrations of non-biotinylated 
OPureA in solution, no appreciable binding of the protein to the immobilized OPureA 
is observed during the injection (Fig. 25). 
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Figure 25. Double-referenced sensorgrams representing the in-solution competition assays 
experiment. Ni(II)-HpNikR injected in a five-fold serial dilution (black line) and Ni(II)-HpNikR 
incubated with equimolar non-biotinylated OPureA (light grey line). The 1:1 complexes were prepared 
at the same concentration of the Ni(II)-bound protein alone. Ni(II)-HpNikR (0.2, 1.0, 5.0, 25.0, 
125.0) nM. 
 
Considering the similar affinity of Ni(II)-HpNikR for OPureA in solution or 
immobilized on the surface, this observation suggests a slow dissociation between 
Ni(II)-HpNikR and OPureA in solution, which prevents further binding of HpNikR 
to the immobilized operator. 
Steady-state affinity between immobilized OPureA and Ni(II)-HpNikR was then 
investigated over a broad range of protein concentrations (from 2 nM to 1 µM) 
injected in a two-fold serial dilutions (Fig. 26). Fitting each independent data set to 
the 1:1 binding isotherm model (Fig. 26 b, Eq. 4) produced an average KD value of 
55.0 ± 14.4 nM, in full agreement with the value previously obtained using ITC 
(56 nM)186, further confirming that the immobilization process did not interfere 
with the biological activity of the OPureA. Moreover, a mean Rmax of 46.4 ± 9.9 RU 
for the different sensor chip preparations employed during the study showed an 
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excellent reproducibility of the immobilization protocol and of the analysis 
conditions (Table 3). 
 
Figure 26 | Double-referenced sensorgrams (a) and equilibrium responses fitted to the Eq. 1 (b) for 
the interaction of Ni(II)-HpNikR, with immobilized OPureA. Protein samples were delivered from 
the lowest to the highest concentration (2, 4, 8, 16, 31, 63, 125, 250, 500 and 1000 nM). 
Intermediate concentrations (8, 16, 31, 63 nM) were injected in duplicate. Interaction displayed in 
the figure is representative of a run carried out on one of the three surface prepared in the study. 
 
Visual inspection of the sensorgrams revealed that the formation of the Ni(II)-
HpNikR–OPureA complex did not reach equilibrium within the 180 s of the 
injection time; instead, a small but continuous increase of the SPR signal upon 
binding was detected, suggesting an interaction more complex than a simple 
binding event. To gain deeper knowledge on the system, a series of holo-protein 
samples were injected over the dsDNA-functionalized surface in a twofold serial 
dilution (2.3–300 nM) (Fig. 27), and the resulting curves were fitted to theoretic 
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interaction models. Non-linear regression analysis using a simple 1:1 binding (eq. 
5) model provided sub-optimal description of the experimental data (Fig. 27), 
requiring the use of more complex theoretical models describing multi-
components reaction mechanisms. 
Chip KD (M) 𝑹 (RU) 
1 4.59 ⋅ 10−8 35.69 
2 4.74 ⋅ 10−8 55.19 
3 7.16 ⋅ 10−8 48.45 
Average (5.5 ± 1.4) ⋅ 10−8 46.4 ± 9.9 
Table 3 Equilibrium dissociation constants KD
 
obtained from the steady-state affinity analysis 
carried out on the three different sensor chip surfaces. Ni(II)–HpNikR was injected from 1 µM to 2 
nM in a two-fold serial dilution in MCK analysis mode 
 
First, a heterogeneous binding model was applied (Eq. 6), which involves two 
independent reactions occurring in parallel. This event could arise from two 
different scenarios: (i) the protein binds to OPureA in two non-equivalent sites, with 
a 1:1 stoichiometry and different kinetics, or (ii) the protein binds to OPureA only in 
one site, with dsDNA existing in alternative forms that interact differently with the 
protein, likely reflecting structure heterogeneity on the surface or non-specific 
binding events187. Second, an interaction model that describes a two-step reaction 
mechanism was considered (Eq. 7), which entails the formation of an initial 
complex, subsequently switching to a more stable conformation that cannot 
dissociate directly in the two initial interactants. Both models provided a better 
description of the experimental data with respect to the 1:1 binding event (Fig. 
27b, c, respectively), as expected from models that can fit multiple parameters 
simultaneously188.  
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Figure 27 | Double-referenced sensorgrams (dark) with different super-imposed theoretical model 
(light) for the same Ni(II)-HpNikR–OPureA interaction. The residual plot for each non-linear 
regression analysis is shown below each data set. (a) 1:1 binding, (b) heterogeneous model, (c) 
two-state interaction mechanism. Samples were delivered from the lowest to the highest 
concentration (2.3, 4.7, 9.4, 18.8, 37.5, 75, 150, 300 nM), with four intermediate concentrations 
injected in duplicate in random order. 
 
However, they present similar values of the statistical parameters χ2 (see Tables 
S2 and S3 in supplementary of the original article) and similar residual plots, and 
therefore, it was not possible to choose, at this stage, one model over the other to 
provide a definitive description of the binding event. The formation and parting of 
the protein–operator complex was thus further investigated through single cycle 
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kinetic titration (SCK) titration, where a series of five Ni(II)-HpNikR samples, 
including a protein concentration able to saturate all the available binding sites, 
were injected over the functionalized surface, and the final dissociation event was 
monitored for an extended period of 600 s (Fig. 28).  
 
Figure 28 | Double-referenced sensorgrams representing the single cycle kinetic titration (SCK) of 
Ni(II)-HpNikR–OPureA interaction. Theoretical curves (light) are superimposed to the experimental 
data (dark) and the relative residual plot is displayed below. The protein was injected from the lowest 
to the highest concentration (2, 10, 50, 250, 1000 nM). On the right side the relative contributions of 
the different binding components to the total response are displayed. (a) Heterogeneous binding 
model, (c2 = 0.63): Total response (black solid), AB1 complex (red dashed), AB2 complex (blue 
dotted), bulk + drift (green dotted-dashed) (b) Two-state reaction mechanism, with a correlated (c2 = 
0.44. T): total response (black solid), AB complex (red dashed), AB* complex (blue dotted), bulk + 
drift (green dotted-dashed). Ni(II)-HpNikR (2, 10, 50, 250, 1000) nM. 
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This experimental setup provided a more balanced number of data points 
between the association and dissociation phases with respect to the classical multi-
cycle approach, providing support for the interpretation of complex interactions 
(Fig. 28a, b). Fitting procedures based on the two-step process produced a slightly 
lower χ2 value (χ2 = 0.44) as compared to the heterogeneous model (χ2 = 0.63), 
supporting a binding mechanism that involves sequential binding events. In order 
to establish whether the reaction shows time-dependence and therefore can be 
described by a two-step mechanism, a fixed concentration of Ni(II)-HpNikR (500 
nM) was delivered by varying the length of the injection (Fig. 29). 
 
Figure 29. Sensorgrams representing the effect of different injection lengths on the dissociation 
event of the HpNikR–OPureA complex in the presence of 4 Ni(II) per tetramer. (From darker to 
lighter: 180 s, 120 s and 60s). Ni(II)-HpNikR 500 nM. 
 
For a simple 1:1 interaction, when all binding sites are occupied, the 
dissociation curves should be independent from the contact time and therefore 
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identical when overlaid116, 188. In the present case, the dissociation event becomes 
slower when the two binding partners are left to interact for increasing periods of 
time (Fig. 29), suggesting a stabilization event involving the Ni(II)-HpNikR–
OPureA complex. In accordance to all evidences provided by the extended 
experimental setup, the two-state binding model was applied. This scheme was 
applied to extrapolate the values of kinetic rate constants: kon1 = (1.9 ± 0.7) Ŋ 105 
M−1 s−1, koff1 = (1.6 ± 1.1) Ŋ 10−2 s−1, kon2 =(3.3 ± 1.2) Ŋ 10−3 s−1, and koff2 = (3.4 ± 
0.5) Ŋ 10−3 s−1, with a global associated KD of 36 ± 11 nM. The entire data sets for 
the kinetic analysis, showing also rate constants calculated for 1:1 binding and 
heterogeneous binding models, are collected in Tables S2, S3, and S4 in the 
supplementary material of the original article. 
 
Isothermal titration calorimetry 
Previous data on the Ni(II)-HpNikR interaction with OPureA, obtained by ITC186, 
were re-analyzed by taking advantage of a novel method, named kinITC, that 
quantifies the kinetics through the analysis of the shape of each ITC injection 
peak182, 183. The presence of a kinetic signal in ITC is revealed by a significant 
variation of the time required for each heat trace to return to the baseline along the 
series of multiple ligand injections, with the largest value reached when the 1:1 
stoichiometry is approached. Therefore, from the raw data, an equilibration–time 
curve (ETC) was derived that reports the equilibration times against the 
stoichiometric ratio corresponding to each injection. A fitting of the curve (χ2 = 
1.8) provided a value for koff = (6.8 ± 0.7) Ŋ 10−3 s−1, from which kon = 1.2 ± 0.1 Ŋ 
105 M−1 s−1 could be derived for the interaction of Ni(II)-HpNikR with OPureA 
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using the known value of KD = 56 nM, provided by ITC steady-state analysis, as 
well as by EMSA and DNase footprinting186. 
 
Ni(II) dependence of the binding mechanism 
The ITC analysis of Ni(II) binding to HpNikR revealed that the protein binds 
four Ni(II) with a 2 + 2 stoichiometry189. This bi-partite Ni(II) binding mode poses 
the question of which form of the protein is competent for dsDNA binding, cis or 
trans, and whether two Ni(II) ions bound per protein tetramer are sufficient to 
activate the protein toward this event. This question was addressed by 
investigating the HpNikR–dsDNA binding in the presence of sub-stoichiometric 
Ni(II) concentrations, using both ITC and SPR (Fig. 30). 
The binding isotherm obtained by ITC for HpNikR binding to OPureA in the 
presence of two Ni(II) ions per tetramer (Fig. 30a) provided an affinity constant 
(KD = 230 ± 20 nM) higher than, but comparable to, the one calculated for the fully 
metal-loaded protein (KD = 56 ± 5 nM). However, the binding stoichiometry was 
significantly lower (n = 0.16 ± 0.01 as compared to n = 0.9 ± 0.1), indicating that 
only ca. 16 % of the protein molecules is competent for dsDNA binding. 
Calculation of the species distribution under these experimental conditions, 
indicates that the fraction of the protein containing four Ni(II) per protein tetramer 
is indeed 18 % at 2:1. The observed stoichiometry is therefore an indicator that 
only the protein bound to four Ni(II) ions is competent for dsDNA binding with 
high affinity, while the occupancy of two metal sites is not sufficient to promote 
protein binding to dsDNA with similarly high constants.  
 104  
This binding behavior was further assessed using SPR, injecting a fixed protein 
concentration of 200 nM, which was previously incubated with 0, 1, 2, 3, and 4 
equivalents of Ni(II) per tetramer. The results showed that both the response and 
the subsequent stabilization effect increase with increasing concentration of Ni(II) 
ions in solution (Fig. 30b and Table in the supplementary material of the original 
article). 
 
Figure 30 | (a) ITC binding isotherm for OPureA (40 µM) titration over HpNikR (4 µM) in the 
presence of 8 µM NiSO4. Fit of the normalized heat of reaction data (dots) is represented as a red 
line. The binding stoichiometry and dissociation constant are KD = 230 nM and n = 0.16 
respectively. (b) Representation of the interaction between 200 nM HpNikR incubated with 
different equivalents of Ni(II) per protein tetramer. Equivalents of Ni(II) in the sample are indicated 
above each sensorgram. Theoretical fitting to a two-state interaction mechanism (orange) are 
superimposed to the experimental data (black). Responses (RU) are proportional to the amount of 
Nickel in the sample. 
 
Interestingly, in the presence of only one Ni(II) equivalent the calculated 
amount of HpNikR loaded with four Ni(II) is negligible, while the rest of the 
protein contains either two or zero Ni(II) bound in comparable amounts. 
Considering that apo-HpNikR did not show any signal in SPR (Fig. 24), the 
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response must derive from the fraction of the protein bound to two Ni(II) 
equivalents. Under these conditions, response is very low and data fitting by a two-
step model or by a 1:1 binding produced qualitatively similar theoretic interaction 
curves (data not shown), suggesting the absence of a stabilization step when only 
two Ni(II) ions are bound to HpNikR. 
 
Mechanistic analysis of the HpNikR–OPureA interaction 
Taken together, the SPR data analysis is consistent with the presence of a two-
step binding event; first, an initial encounter between protein and dsDNA 
establishes an intermediate and subsequently, a conformational rearrangement 
leads toward the final, highly stable, HpNikR–OPureA complex. The nature of this 
stabilization event can be interpreted considering previously reported data: (i) 
calorimetric experiments indicated that four Ni(II) ions bind to the MBD of 
HpNikR (and EcNikR) and produce a conformational effect that propagates far 
away from the metal binding sites155, 186, 189; (ii) small angle X-ray light scattering 
(SAXS)190, 191, NMR spectroscopy192 and analysis of protein dynamics192 
consistently show that this conformational change does not correspond to a 
rearrangement of the protein structure toward a specific cis conformation able to 
bind dsDNA, but rather involves an increase of mobility of the peripheral DBDs 
through the flexible linker connecting it to the MDB. This phenomenon allows the 
protein to span more efficiently a larger conformational ensemble and facilitates 
the search for the protein conformation optimal to bind dsDNA through an induced 
fit mechanism. Indeed, the isolated MDB and DBD maintain their functional 
properties of Ni(II) and dsDNA binding, respectively, indicating that the function 
of the protein as a nickel-dependent dsDNA interactor resides in their relative 
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position on the dsDNA operator193. In this view, we suggest that the stabilization 
event observed in the SPR analysis is related to the acquired ability of the protein 
to assume the cis conformation, unlocking the N-terminal DBDs as compared to 
the C-terminal MBD. These findings support the proposition of an adaptive 
mechanism promoted by the presence of both the OPureA and four Ni(II) ions per 
protein tetramer. 
 
Conclusions 
The results obtained in the present study extend our knowledge on the 
mechanism of HpNikR–OPureA interaction, highlighting a two-step binding 
mechanism, which leads to the formation of a high stable complex in the presence 
of 4 Ni(II) equivalents per protein tetramer. Moreover, the implementation of a 
validated SPR-based assay constitutes a suitable starting point to develop new 
methods for screening lead candidates to modulate this protein–dsDNA 
interaction, aimed at the eradication of H. pylori. 
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Materials and methods 
 
Chemicals and instrumentation 
Streptavidin, N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 
ethylenediaminetetraacetic acid (EDTA), sodium chloride (NaCl), polyoxyethylenesorbitan 
monolaurate (p-20), sodium dodecyl sulfate (SDS), and Ni(II) sulfate hexahydrate (NiSO4 Ŋ 6 H2O) 
were purchased from Sigma-Aldrich (Milan, Italy). Research-grade CM 5 sensor chips, sodium 
acetate buffer 10 mM pH 5.0, 10X HEPES buffer saline (HBS-EP+) (consisting of HEPES 0.1 M, 
NaCl 1.5 M, EDTA 30 mM, p-20 0.5 % v/v), and the amine coupling kit, consisting of N-ethyl-N-
(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide (NHS) and ethanolamine 
hydrochloride-NaOH (pH 8.5; 1 M), were purchased from GE Healthcare Bio-Sciences (Uppsala, 
Sweden). All surface plasmon resonance (SPR) measurements were performed with a BiacoreTM 
X100 system (GE Healthcare Bio-Sciences) equipped with an in-line degasser and thermostated at 
25 °C. Data were analyzed and processed using the BIAevaluation 4.1 software. 1X (HBS-EP) 
(1:9, v/v) (pH 7.4) solution was used as immobilization buffer, while a solution containing HEPES 
20 mM, NaC189l 150 mM and p-20 0.05 % (v/v) (pH 7.0) was used as running buffer. Interaction 
analyses were all carried out at constant flow rate of 30 µL min−1. Isothermal titration calorimetry 
(ITC) experiments were performed using a VP-ITC (Microcal, Malvern) equilibrated at 25 °C as 
previously described180. 
 
Surface plasmon resonance 
Sample preparation 
Apo-HpNikR tetramer (69 kDa) was expressed and purified following a previously described 
protocol189 and stored at −80 ° C in 20 mM HEPES buffer at pH 7.0 containing 150 mM NaCl. A 
10 mM NiSO4 water solution was diluted at a suitable concentration with running buffer and mixed 
with apo-NikR each day prior to the analysis to prepare stock solutions of the holo form of the 
protein, referred as Ni(II)-HpNikR in this work, and containing four Ni(II) ions per tetramer. All 
further dilutions of both apo- and holo-NikR were performed directly in running buffer. 
Single-strand oligos with the sequence of the urease operator (sense: 5′-
ATATAACACTAATTCATTTTAAATAATAATTA-3′; antisense: 5′-
TAATTATTATTTAAAATGAATTAGTGTTATAT-3′) containing ten additional bases at 5′ end 
(sense: 5′-CGCTTCAAAA-3′; antisense: 5′-TTTTGAAGCG-3′) were purchased from Life Science 
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and annealed into the double-strand urease operator (OPureA). The sense oligo was covalently 
linked, at the 5′ end, to a biotin molecule required for the surface preparation in the SPR 
experiments, while the antisense was used as such. Similarly, non-extended and non-biotinylated 
double-strand OPureA was purchased and prepared for in-solution experiments. 
 
Surface preparation and validation 
Streptavidin was diluted at 100 µg mL−1 in sodium acetate buffer 10 mM pH 5.0 and immobilized 
through amine coupling reaction; subsequently, biotinylated OPureA was captured over the 
previously functionalized surface exploiting the biotin–streptavidin affinity194. Flow cell 1 
(reference flow cell) and flow cell 2 (active flow cell), of a CM5 sensor chip, were activated by 
injection of a freshly prepared EDC (0.4 M) and NHS (0.1 M) mixture for 7 minutes at a flow rate 
of 10 µL min−1. Then, the appropriate amount of streptavidin was attached on both channels 
exploiting the target level function provided from the BIAcore control software. Afterwards, the 
remaining active esters were quenched by injecting Ethanolamine-HCl (1 M) at pH 8.5 for 7 min at 
a flow rate of 10 µL min−1. Immediately after streptavidin immobilization, the surface was washed 
with three consecutive 30 s injections of a 50 mM NaOH/1 M NaCl solution, followed by two 15 s 
injections of 0.05% SDS and three 60 s injections of running buffer. Then, after a stable baseline 
was achieved, biotin-bound OPureA, diluted at 6.25 nM in running buffer, was captured over the 
active flow cell at 5 µL min−1 flow rate. Subsequently, three consecutive 15 s injections of SDS 
0.05 % and several 180 s injections of running buffer were performed in order to remove any 
loosely bound DNA and stabilize the surface. 
Following the immobilization process, Ni(II)-HpNikR and apo-HpNikR samples were delivered in 
a wide range of concentrations (2 to 1000 nM) over the sensor surface in order to assess the 
biological activity of the tethered OPureA. The specificity of the molecular recognition was also 
evaluated in a similar experimental setup, where Ni(II)-HpNikR samples prepared at five different 
concentrations (0.2, 1.0, 5.0, 50, and 125 nM), either in the absence or the presence of equimolar 
amount of soluble non-biotinylated OPureA, were incubated for at least 30 min, and injected over the 
functionalized surface. Finally, the contribution of the mass transport limitation (MTL) to the 
overall interaction was assessed. 
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Ni(II)-HpNikR–OPureA interaction analysis. 
The Ni(II)-HpNikR–OPureA interaction was analyzed using classical multi-cycle kinetic (MCK) and 
single-cycle kinetic (SCK) approaches over a broad series of protein concentrations, ranging from 2 
to 1000 nM. Replicates for the interaction were collected over a total of three freshly prepared 
sensor chip surfaces, and results were independently fit to the appropriate binding model. Protein 
samples were delivered in a twofold or fivefold serial dilution, with association and dissociation 
events monitored for 180 and 400 s, respectively. Regeneration was achieved with two consecutive 
injections of 15 µL of SDS 0.2 % (w/v) and an additional stabilization period of 300 s, during 
which running buffer was flowed over the sensor chip surface.  
For steady state analysis, Ni(II)-HpNikR samples were delivered from the lowest to the highest 
concentration (2, 4, 8, 16, 31, 63, 125, 250, 500 and 1000 nM). Intermediate concentrations (8, 16, 
31, 63 nM) were injected in duplicate. 
For MCK experiments, Ni(II)-HpNikR was injected from 2.3 nM to 300 nM in a two-fold serial 
dilution; intermediate concentrations (9.4, 18.8, 37.5 nM) were injected in duplicate in random 
order to monitor the stability of the system and buffer was injected every four cycles as blank for 
double referencing purposes. For SCK experiments, Ni(II)-HpNikR was injected from 2 to 1000 
nM in a five-fold dilution, dissociation was monitored for an extended period of 600 s. 
In order to investigate the time-dependence of the reaction, the protein was also injected at a fix 
concentration of 500 nM with three different contact times (60, 120, and 180 s). 
The effect of Ni(II) concentration in the environment on the HpNikR–OPureA interaction was 
assessed by incubation of 200 nM apo-HpNikR solutions with different equivalents of Ni(II) per 
tetramer, yielding samples with 0:1, 1:1, 2:1, 3:1, and 4:1 metal-to-protein ratios. Then, the five 
different solutions were delivered in random order over the active surface. To avoid Ni(II) 
contamination among samples, a regeneration step, consisting of a 60-s injection of 300 mM EDTA 
at pH 8.0 in water followed by a 180-s injection of running buffer, and a stabilization period of 300 
s, was performed. 
 
Data evaluation 
Signals arising from the active flow cell were corrected for the signals generated from the reference 
flow cell, and against an average of the blank injections performed during the analysis to obtain 
double-referenced sensorgrams113. For the steady state analysis, the equilibrium response 
(resonance units, RU) reached 5 s before the injection stops was measured and plotted against the 
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protein concentration to obtain the equilibrium dissociation constant KD. Data sets were analyzed 
assuming a 1:1 isotherm binding model, defined by the Eq. (4). 
For kinetic and mechanistic analysis, real-time interaction curves (sensorgrams) were globally 
fitted to three different theoretic models: 1:1 binding, heterogeneous binding, and two-state 
reaction, equation 5, 6 and 7 respectively. Sensorgrams traces obtained for the Ni(II)HpNikR–
OPureA interaction were globally fitted to three different interaction models: two-state, 1:1 binding 
and heterogeneous binding. Each fitting model is reported with the associated statistical parameter 
χ2, expressing the goodness of fit. 
The 1:1 binding, the heterogeneous ligand binding and the two-state binding models are 
extensively discussed in the results section while the heterogeneous binding scenario has been ruled 
out. Evidences against its use are presented and will be briefly discussed here. The heterogeneous 
analyte binding takes place when two species compete for the same binding site on the immobilized 
ligand, and it is primarily intended to be used when two analytes of different molecular weight are 
deliberately mixed in solution195. In those conditions, the binding of the low molecular weight 
analyte is hardly detected, but because it involves binding sites on the surface, it will affect the 
observed sensorgrams. In principle, a situation where two different populations of the same analyte 
are together in solution can also give rise to a heterogeneous analyte binding scenario. We ruled out 
this circumstance for the system under investigation, because a fitting procedure based on this 
model, considering 10% of the total concentration represented by a different analyte of the same 
molecular weight as holo-NikR, resulted in a quantitatively worse description of the binding 
process as compared to the other multi-components models applied. Furthermore, this fitting 
procedure is not able to take into account the time-dependency, which strongly characterizes the 
monitored interaction. Moreover, the presence of previous data proposing an induced-fit 
mechanism between holo-HpNikR and OPureA, strongly supported the proposed two-state reaction, 
which was employed to extrapolate kinetic rate constants from the SPR analysis. During data 
evaluation, residual plots and the statistical parameter χ2 were used to choose the best theoretical 
description of the experimental results and to extrapolate the kinetic rate constants. Data collected 
for the samples containing different equivalents of Ni(II) per HpNikR tetramer were fitted 
independently to the two-step interaction model. Kinetic analysis in these latter experiments should 
be taken as a qualitative description of the binding event rather than quantitative, because the 
interactions were monitored for a single protein concentration. 
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Isothermal titration calorimetry 
All ITC experiments were performed in 20 mM HEPES buffer at pH 7.0, containing 150 mM 
NaCl, under identical conditions as previously reported for the dsDNA titration of apo-HpNikR and 
Ni(II)-HpNikR186. In order to derive the kinetic parameters of the HpNikR–OPureA interaction, ITC 
data obtained from the titration of dsDNA onto Ni(II)-HpNikR186 were used as input for 
equilibration–time curve (ETC) analysis182 performed using the AFFINImeters software 
(https://www.affinimeter.com/). This method provided an ETC curve that shows the equilibration 
time Τ (the time that heat trace needs after every injection to go back to baseline) versus the Ni(II)-
HpNikR stoichiometric ratio. A fit of the experimental data was performed according to Eq. 8, 
considering an instrumental response time of 8.2 ± 0.5 s, as indicated by the manufacturer: 
 
Τ = 1 / c
koff [(1 / c + s+1)2 − 4s ]1/2
  (8) 
 
where c = [HpNikR]/KD, KD and koff are the equilibrium and kinetic dissociation constants, 
respectively, and s = [OPureA]/ [HpNikR]. This method allowed us to calculate koff for a single-step 
interaction model. The association kinetic constant kon was derived using the equation KD = kon / 
koff, based on the KD value previously reported for the Ni(II)-HpNikR–OPureA interaction186. The 
data points of the ETC that occur after the binding saturation were deleted using the default option 
of the AFFINImeter software, as they only describe the dsDNA dilution in the protein solution, and 
have a low signal-to-noise ratio. In order to derive the thermodynamic parameters for the 
interaction of HpNikR loaded with two equivalents of Ni(II), a OPureA solution (40 µM, 30 × 10 µL 
injections) was titrated onto a protein solution (4 µM) in the presence of 8 µM Ni(II), as previously 
described186. Integration of the raw data to obtain the binding isotherm was performed using 
NITPIC program196. 
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Abstract 
Caffeic acid-derived polyethers are a class of natural products isolated from the 
root extracts of comfrey and bugloss, which are endowed with intriguing 
pharmacological properties as anticancer agents. The synthesis of new polyether 
derivatives is achieved through ring-opening polymerization of chiral 2,3-
disubstituted oxiranes, whose absolute configurations define the overall 
stereochemistry of the produced polymer. The absolute stereochemistry of one of 
these building blocks, methyl trans-3-(3,4-dimethoxy-phenyl)glycidate (3), was 
therefore characterized by the combination of enantioselective high-performance 
liquid chromatography (HPLC), electronic circular dichroism (ECD) spectroscopy, 
and time-dependent density functional theory (TD-DFT) calculations. Initial 
efforts aiming at the isolation of enantiomers by means of a standard preparative 
HPLC protocol followed by offline ECD analysis failed due to unexpected 
degradation of the samples after collection. The stopped-flow HPLC-CD approach, 
by which the ECD spectra of enantiomers are measured on-line with the HPLC 
system, was applied to overcome this issue and allowed a fast, reliable, and 
chemical-saving analysis, while avoiding the risks of sample degradation during 
the collection and processing of enantiomeric fractions. Subsequent TD-DFT 
calculations identified (2S,3R)-3 as the first eluted enantiomeric fraction on the 
Lux Cellulose-2 column, therefore achieving a full stereochemical characterization 
of the chiral oxirane under investigation. 
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Introduction 
Enantiomerically pure oxiranes are a valuable class of chiral compounds 
currently employed in synthetic organic chemistry as electrophilic synthons for 
several industrial and pharmaceutical applications, such as the synthesis of 
polyethers through ring-opening polymerization197-200. A new series of caffeic 
acid-derived polyethers (Fig. 31), poly[3-(3,4-dihydroxyphenyl)glyceric acid] (1) 
and poly[methyl-3-(3,4-dihydroxyphenyl)glycerate] (2), was isolated and 
identified in the water-soluble, high-molecular weight (>1000 kDa) fraction 
obtained from root extracts of different species of comfrey (Symphytum asperum, 
S. caucasicum, and S. officinale) and bugloss (Anchusa italica), all belonging to 
the Boraginaceae family201-203. 
 
Figure 31 | Chemical structures of the caffeic acid-derived polyethers mentioned in the article 
(compounds 1, 2, and 4) and of methyl 3-(3,4-dimethoxyphenyl) glycidate (compound 3) 
 
The immunomodulatory properties of polyethers 1 and 2 were assessed by in 
vitro and in vivo assays, which also unveiled excellent antineoplastic activity 
against human prostate cancer, as shown by the dose-dependent inhibition of 
22Rv1-induced tumor growth in athymic mice, and antimetastatic properties 
against melanoma cell lines, as demonstrated by the inhibition of B16M cell 
adhesion to cultured hepatic sinusoidal endothelial cells204. Considering the 
 116  
pharmacological profiles of polyethers 1 and 2, the synthesis of new caffeic acid-
derived polyethers would constitute a promising route toward the development of 
potential drug candidates. 
Recently, the use of 3-arylglycidic acid derivatives as chiral building blocks for 
the production of such polyethers has been reported; in particular, ring-opening 
polymerization of methyl 3-(3,4-dimethoxyphenyl)glycidate (3, Fig. 31) led to the 
formation of poly[methyl 3-(3,4-dimethoxyphenyl) glycerate] (4, Fig. 31), a fully 
methylated analog of the natural polyethers 1 and 2205 (Fig. 31). The structure of 
polymer 4 was found to be linear, despite the low reactivity of bulky 2,3-
disubstituted oxiranes and the possible formation of branched polymers by Friedel-
Crafts alkylation of the aromatic substituent. However, the stereoselectivity of the 
mechanism of ring opening and the stereochemistry of the resulting backbone are 
not fully characterized; the first step needed for the elucidation of these aspects is 
the assessment of the absolute configuration of the building block. 
Compound 3 can be synthesized by Darzens condensation206 of veratraldehyde 
with methyl chloroacetate yielding a racemic mixture of the pure trans-
diastereomer as confirmed by 1H-NMR analysis205, or by Shi epoxidation207 of 
methyl 3,4-dimethoxycinnamate with oxone. 
In both situations, the relative configuration of the substituents on the oxirane 
ring is known; as a consequence, a complete stereochemical characterization of 
trans-3 requires further analyses on its purified enantiomers. If a chiral compound 
is not obtained as a pure enantiomer through synthesis, as in the case of trans-3, 
separation techniques such as enantioselective high-performance liquid 
chromatography (HPLC) can be employed in combination with chiroptical 
spectroscopies, such as electronic circular dichroism (ECD), in order to assign the 
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correct absolute configuration to its enantiomers. Two possible strategies can be 
used for this purpose: 1) isolation of the enantiomers by preparative 
enantioselective HPLC followed by offline ECD spectroscopic analysis on the 
purified enantiomeric fractions; 2) hyphenation of HPLC with an ECD detection 
system (labeled HPLC-CD to avoid confusion with electrochemical detection) and 
online determination of the ECD spectra of enantiomers during the 
enantioselective HPLC separation by means of stopped-flow measurements80, 208. 
The preparative HPLC approach is useful beyond the purposes of stereochemical 
characterization, allowing the preparation of highly pure enantiomeric samples in 
the absence of enantioselective synthetic procedures209. The HPLC-CD approach, 
on the other hand, provides a valuable analytical tool to avoid the time-consuming 
collection of pure enantiomers; moreover, the risk of contamination and 
degradation of collected samples, arising by the necessary step of solvent 
evaporation, is completely avoided. 
ECD spectroscopy is able to provide all the necessary information at the 
molecular level for discrimination and characterizion of the absolute configuration 
of chiral molecules84; nevertheless, the observed properties cannot be readily 
translated into the corresponding chemical structures. The chiroptical properties of 
enantiomers must therefore be derived by means of an appropriate theoretical 
method and subsequently compared to the experimental results. 
Currently, quantum chemical calculations based on time-dependent density 
functional theory (TD-DFT) is the most popular approach for stereochemical 
characterization studies on pharmaceutical compounds, thanks to their accurate 
predictions of the molecular properties (including ECD) for medium-to-large sized 
molecules with relatively limited computational effort210, 211. 
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This article reports the stereochemical characterization of the enantiomers of 
trans-3, whose absolute configurations have been assessed by means of 
enantioselective HPLC, ECD spectroscopy, and TD-DFT calculations; both the 
preparative HPLC and the stopped-flow HPLC-CD strategies were applied, and 
the advantages of the stopped-flow approach for the analysis of trans-3 are 
discussed. 
 
Results and Discussion 
Preparative HPLC and Offline ECD Analysis 
The collection of the enantiomeric fractions of trans-3 was carried out on a Lux 
Cellulose-4 column (CSP: cellulose tris (3-methyl-4-chlorophenylcarbamate)), 
which provided long retention times (t0 = 1.65 min; k1 = 18.60; k2 = 35.15) and 
high enantioselectivity (α = 1.89)212; the chromatographic performance of Lux 
Cellulose-4 was therefore suitable for a preparative HPLC application.  
Unfortunately, the offline ECD and UV spectra of the resulting fractions, as 
obtained after collection, evaporation of the mobile phase, and dissolution in 2-
propanol, showed an unexpected behavior (Fig. S1 in the Supporting Information 
of the original article). Although the ECD profiles in the high-energy spectral 
region (λ < 250nm) displayed mirror-image bands of equal magnitude and 
opposite sign, the broad low-energy ECD band was found to be negative for both 
samples, indicating that the analyzed fractions were not in enantiomeric 
relationship. Furthermore, the shifts observed for the absorption maxima in the UV 
spectra of both samples with respect to the racemic mixture was strong 
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experimental evidence leading to the conclusion that a chemical transformation of 
the collected enantiomeric fractions of trans-3 had occurred. 
Stopped-Flow HPLC-CD Analysis 
The enantiomers of trans-3 can be easily separated with high values of 
enantioselectivity and resolution on most of the commercially available 
polysaccharide-based chiral stationary phases (CSPs)18; as a consequence, the 
enantioselective HPLC analyses on trans-3 described in this article were 
performed on two different columns, namely, Lux Cellulose-4 and Lux Cellulose-
2 (CSP: cellulose tris(3-chloro-4-methylphenylcarbamate)). The latter column is 
able to resolve the enantiomers of trans-3 with slightly lower enantioselectivity 
than the former (α = 1.81); however, the shorter retention times (t0 = 2.96 min; k1 
= 6.55; k2 = 11.86) and the excellent resolution (Rs = 10.24) provided by Lux 
Cellulose-2 (Fig. 32) were more suitable for analytical purposes and therefore 
preferred for the application of the stopped-flow HPLC-CD approach. 
 
Figure 32 | Enantioresolution of trans-3 on the Lux Cellulose-2 column (mobile phase: n-hexane/2-
propanol, 80:20 v/v; flow rate: 1 mL min 1; λ = 240 nm). 
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The stopped-flow spectra of the two chromatographic fractions show a clear 
mirror-image relationship of all the ECD bands in the whole spectral range of 
analysis and a close correspondence of the absorption UV profiles with respect to 
rac-trans-3, suggesting that the two fractions are indeed in enantiomeric 
relationship (Fig. 33). 
The analytical protocol for stopped-flow measurements was developed in order 
to reduce the influence of baseline drifts to a minimum and to improve the signal-
to-noise ratio of the spectroscopic response, which is an important issue of online 
HPLC-CD measurements. The developed stopped-flow HPLC-CD strategy was 
therefore successfully employed to acquire high-quality experimental ECD spectra 
of the enantiomers of trans-3, bypassing the collection step required by the 
preparative HPLC approach and drastically reducing the risk of degradation. 
 
Figure 33. ECD and UV spectra of rac-trans-3 (in 2-propanol) and of the enantiomeric fractions of 
trans-3 (in mobile phase), as measured by stopped-flow HPLC-CD analysis on the Lux Cellulose-2 
column. Solid: first eluted fraction. Dashed: second eluted fraction. Dotted: rac-trans-3 
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Absolute Configuration Assessment 
The last step of the characterization process was aimed at the theoretical 
determination of the chiroptical properties of (2S, 3R)-3 by means of TD-DFT 
calculations. The preliminary MM conformational search on (2S, 3R)-3 identified 
34 low-energy conformers (Table S1 in the Supporting Information of the original 
article), which were subsequently optimized at the RI-B97D/ def2-
TZVPP’D/IEFPCM level. The conformational flexibility of trans-3 (Figure S2, 
Table S2, in the Supporting Information of the original article) is limited to the 
orientation of substituents with respect to the oxirane ring (dihedrals α and β for 
the methoxycarbonyl and 3,4-dimethoxyphenyl substituents, respectively) and to 
the orientation of the methoxy groups (dihedrals φ, ω1, and ω2 for the 
methoxycarbonyl, 3-methoxyphenyl, and 4-methoxyphenyl groups, respectively). 
After DFT optimization, some conformers converged to the same geometry, 
reducing the number of equilibrium conformers to 28 after clustering; the limited 
flexibility of (2S, 3R)-3 was confirmed by the observation that the four lowest-
energy geometries account for almost 90% of equilibrium conformers (Table S3 in 
the Supporting Information of the original article), with conformer (2S, 3R)-3.25 
being by far the most populated (χG=45.4%). The subsequent TD-DFT calculations 
at the PBE0/def2-TZVPP’D/ IEFPCM level were performed on the 10 conformers 
showing ΔG values within the threshold of 2.5 kcal/mol–1. The conformationally 
averaged theoretical spectra of (2S,3R)-3 (Fig. 34) show that the three main 
absorption bands are expected to give rise to positive Cotton effects: although the 
employed TD-DFT level generally overestimates the transition energies of trans-3, 
the ECD and UV profiles are reproduced with a reasonable degree of accuracy and 
allow assigning a (2S, 3R) absolute configuration to the first eluted fraction on the 
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Lux Cellulose-2 column. Consequently, the elution order of the enantiomers of 
trans-3 on the Lux Cellulose-2 column, under the chromatographic conditions used 
in this study, was found to be: (2S, 3R)-3, (2R, 3S)-3. 
 
Figure 34 | Stopped-flow ECD and UV spectra of the enantiomeric fractions of trans-3 eluted from 
Lux Cellulose-2 (bottom/left axes), compared to the theoretical spectra of (2S,3R)-3 (top/right 
axes). Solid: stopped-flow first eluted fraction. Dashed: stopped-flow second eluted fraction. 
Dotted: theoretical spectra.  
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Conclusion 
In this article the absolute stereochemistry of the 3-arylglycidic acid derivative 
trans-3 was successfully characterized by the combination of enantioselective 
HPLC, ECD spectroscopy, and TD-DFT calculations. Knowledge of the absolute 
configuration for the enantiomers of this chiral building block is an important 
prerequisite for elucidating the stereoselectivity of its polymerization by ring 
opening, ultimately leading to a better stereochemical control in the synthesis of 
caffeic acid-derived polyethers, a new class of biologically active molecules of 
natural origin. The discrimination between the enantiomers of trans-3 was initially 
attempted using a preparative HPLC protocol, in which the enantiomeric fractions 
were isolated and processed for an offline ECD analysis; unfortunately, the 
application of this standard approach failed due to the realistic occurrence of 
incidental sample degradation during the post-collection processing of fractions. 
The solution to this unexpected problem was provided by the stopped-flow HPLC-
CD strategy, which provided a fast, reliable, and chemical-saving alter- native for 
the acquisition of the experimental ECD and UV spectra of the enantiomers of 
trans-3 while avoiding the risk of post-collection degradation. In this framework, 
the hyphenation of enantioselective HPLC methods with detection systems based 
on ECD spectroscopy was confirmed as a powerful analytical tool for the 
stereochemical characterization of chiral molecules, in particular when combined 
with computational methods based on the TD-DFT calculation of theoretical 
chiroptical properties. 
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Material and Methods  
 
HPLC-CD analysis 
Preparative HPLC Collection 
Racemic methyl trans-3-(3,4-dimethoxyphenyl)glycidate (rac-trans-3) was synthesized by Darzens 
reaction, according to a reported procedure205; veratraldehyde and methyl chloroacetate were 
purchased from TCI (Tokyo, Japan). The enantiomers of trans-3 were then obtained by preparative 
HPLC collection performed on an Agilent (Waldbronn, Germany) 1200 HPLC system equipped 
with a G1367C HiP ALS-SL autosampler, a G1316B TCC-SL temperature controller, a G1311A 
quaternary pump, a G1314D VWD variable wavelength detector (detection wavelength: 220 nm), 
and the Chemstation software package (v. B.03.02-SR2) for instrument control and data 
processing. The enantioresolution of trans-3 was achieved on a Lux Cellulose-4 column (250 × 4.6 
mm I.D, 5 µm particle size), kindly provided by Phenomenex (Torrance, CA), using a n-hexane/2-
propanol 80:20 (v/v) mixture as mobile phase at a 1 mL min−1 flow rate, following a previously 
reported protocol212. HPLC-grade solvents were purchased from Carl Roth (Karlsruhe, Germany). 
The collected fractions were subsequently dried under vacuum and submitted to spectroscopic 
analysis. 
 
Offline ECD Analysis 
Offline ECD and UV analysis was carried out in the 350–200 nm spectral range on rac-trans-3 and 
on the two enantiomeric fractions collected after resolution on the Lux Cellulose-4 column. 
Samples were prepared in HPLC-grade 2-propanol (Sigma-Aldrich, Milan, Italy) at a nominal 
concentration of 0.015 mg mL−1 for the two collected enantiomeric fractions, while a 0.05 mg mL−1 
concentration was used for rac-trans-3. Spectra were measured on a Jasco (Tokyo, Japan) J-810 
spectropolarimeter equipped with a PTC-423S Peltier-type temperature control system, using a 
1mm pathlength quartz cell (Hellma, Milan, Italy), a 2 nm spectral bandwidth, a 50 nm min−1 
scanning speed, a 2 s data integration time, a 0.2 nm data pitch and three accumulation cycles. 
Instrument control and data processing were performed with the Jasco Spectra Manager 2 software 
package. 
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Stopped-Flow HPLC-CD Analysis 
The spectroscopic analysis was repeated using the stopped-flow HPLC-CD technique on an HPLC 
system consisting of a Jasco PU-980 pump, a LG-2080-02 ternary gradient unit, a DG-2080-53 
degasser, a Jones (Lakewood, CO) model 7955 column chiller, a Rheodyne (Cotati, CA) 7725i 
syringe loading injector, and a 20 µL sample loop; this system was connected to the Jasco J-810 
spectropolarimeter, equipped with a 10 mm pathlength HPLC flow cell and a Rheodyne 7010 
injector setup as a three-way valve for stopped-flow measurements. The enantioresolution was 
achieved on a Lux Cellulose-2 column (250×4.6mm I.D, 3µm particle size), purchased from 
Phenomenex (Castel Maggiore, Italy), using a n-hexane/2-propanol 80:20 (v/v) mixture as mobile 
phase at a 1 mL min−1 flow rate, in accordance with a previously published study on the 
enantioresolution of chiral 3-arylglyceric acid derivatives212; HPLC-grade solvents were purchased 
from Sigma-Aldrich. The analysis was carried out on 0.5 mg mL−1 samples of rac-trans-3 dissolved 
in mobile phase. The enantiomeric fractions of rac-trans-3 were then stopped inside the HPLC flow 
cell during their elution and analyzed by full-spectrum ECD spectroscopy in the 350–215nm 
spectral range, using a 4 nm spectral bandwidth, a 50 nm min−1 scanning speed, a 1 s data 
integration time, a 0.2 nm data pitch and three accumulation cycles. Stopped-flow spectra were 
blank-corrected using stopped-flow measurements of the mobile phase in the same conditions, 
which were repeated before and after each measurement on the fractions in order to correct baseline 
drifts. Each enantiomeric fraction was analyzed three times according to this protocol, and the 
resulting stopped-flow spectra were normalized at the maximum of the lowest-energy absorption 
band (λmax = 281 nm) in order to account for the different instantaneous concentrations inside the 
HPLC flow cell. Instrument control and data processing were performed with the Jasco ChromNav 
and Spectra Manager 2 software packages. 
 
Computational spectroscopy 
 
DFT Conformational Analysis 
A preliminary molecular mechanics (MM) conformational search was carried out on (2S, 3R)-3 
using the MMFF94s force field19 and the Spartan’02 software package213. A relative energy 
(ΔEMM) threshold value of 5 kcal mol 1 was used to identify the lowest-energy conformers. DFT 
geometry optimization and frequency calculations were carried out on the identified MM 
conformers using the Gaussian 09 (Rev. D.01) software package214. The dispersion-corrected 
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generalized gradient approximation functional B97D215 was used in combination with the IEFPCM 
solvation model for 2-propanol216, the resolution of identity (RI) approximation217, and a truncated 
version of the Ahlrichs-type, triple-ζ valence plus double polarization basis set, devoid of d 
functions on hydrogen atoms and f functions on heavy atoms and augmented with a set of diffuse 
functions (def2-TZVPP’D)211, 218. Conformational clustering was performed on optimized 
geometries having root mean square deviations (RMSD) below 0.001 Å for heavy atoms; geometry 
alignment and RMSD determination were performed using the VMD molecular graphics 
software219. A relative free energy (ΔG) threshold value of 2.5 kcal mol−1 was used to identify the 
low-energy equilibrium conformers for TD-DFT calculations. Boltzmann statistics at 298.15 K and 
1 atm was subsequently employed to determine the population of conformers at equilibrium based 
on ΔG values (χG). 
 
TD-DFT Computational Spectroscopy 
TD-DFT calculations were performed on the optimized conformers of (2S, 3R)-3 using the 
Gaussian 09 (Rev. D.01) software package214. The exchange-correlation PBE0 functional220-222 was 
used in combination with the IEFPCM solvation model for 2-propanol216 and the truncated def2-
TZVPP’D basis set211, 218. The theoretical values of rotational strengths (Rj), oscillator strengths 
(fj), and excitation wavelengths (λj) were calculated for the 50 lowest-energy electronic transitions 
of each conformer; the corresponding theoretical ECD and UV spectra were derived by 
approximation of Rj and fj values to Gaussian functions of defined bandwidth (Δσ = 0.3 eV) and 
summation over all excited states210, 223. The overall ECD and UV spectra of (2S,3R)-3 were 
derived by conformational averaging according to the ΔG-based Boltzmann distribution of 
conformers, and subsequently compared to the experimental spectra of the enantiomeric fractions 
recorded in stopped-flow mode during the HPLC analysis on the Lux Cellulose-2 column. Detailed 
results for the computational study on trans-3 are given in the Supporting Information on the 
original article. 
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Abstract 
SMYD3 is a histone lysine methyltransferase that plays an important role in 
transcriptional activation as a member of an RNA polymerase complex, and its 
oncogenic role has been described in different cancer types. In the present study, 
the expression and activity of SMYD3 was investigated in a preclinical model of 
colorectal cancer (CRC) and a strong upregulation throughout tumorigenesis both 
at the mRNA and protein level was found. Results showed that RNAi-mediated 
SMYD3 ablation impairs CRC cell proliferation indicating that SMYD3 is 
required for proper cancer cell growth. These data, together with the importance of 
lysine methyltransferases as a target for drug discovery, prompted a virtual 
screening to identify new SMYD3 inhibitors by testing several candidate small 
molecules. One of these compounds (BCI-121) induces a significant reduction in 
SMYD3 activity in CRC cells, as suggested by the analysis of global H3K4me2/3 
and H4K5me levels. SPR analysis further supported the in silico and in vivo 
findings. The mode of action for BCI-121 was tested through a competition assay, 
in which H4 and BCI-121 contend the methylation pocket on SMYD3. The 
presence of the inhibitor in solution lowered considerably the response of H4 
alone, indicating competition for the same binding site occurred. These results 
represent the proof of principle that SMYD3 is a druggable target and suggest that 
new compounds capable of inhibiting its activity may prove useful as novel 
therapeutic agents in cancer treatment. 
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Introduction 
Cancer cell fate is governed by an intricate network of signaling pathways that 
intersect with epigenetic regulators at the chromatin level. Indeed, any altered 
signaling cascade can induce a perturbation of chromatin structure and functions, 
resulting in modulation of gene expression224, 225. Major mechanism regulating 
chromatin dynamics is the post-translational modification of histone proteins. 
Histone methylation is an important and widespread type of chromatin 
modification that is known to affect biological processes involved in several types 
of cancer226-229. 
The histone methyltransferase SET/MYND Domain Type of Zinc Finger 
(SMYD3), a member of the subfamily of SET domain-containing proteins230, has 
been found overexpressed in different types of tumors: breast, gastric, pancreatic, 
colorectal, lung cancer, and hepatocellular carcinoma231-233. Importantly, it has 
been demonstrated that complete loss of SMYD3 function does not lead to a 
visible phenotype in mouse models, suggesting that the use of small molecules 
capable of impairing SMYD3 activity as new anticancer agents might be 
associated with reduced side effects compared with other chemotherapeutics. 
However, SMYD3 overexpression in normal cells is sufficient to accelerate cell 
growth and has a key role in the activation of genes downstream of pathways 
involved in tumor cell transformation and migration234, 235. Several studies have 
been designed to explore the oncogenic activity of SMYD3. Initially, SMYD3 was 
described as a histone H3K4-specific di- and tri-methyltransferase eliciting its 
oncogenic effect through transcriptional activation of its downstream target 
genes236-238; however, recent studies identified histone H4K5 as a preferred 
substrate in in vitro binding assays. Besides, it has been shown that SMYD3 is 
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required for H4K5 methylation in culture and that its enzymatic activity is 
important for maintaining the transformed cellular phenotype associated with high 
SMYD3 expression239. 
SMYD3 oncogenic activity also involves functional interactions with non-
histone proteins (e.g., VEGFR1, estrogen receptor [ER]) in the cytoplasm that 
regulate cancer cell proliferation and survival. Indeed, SMYD3 methylates 
VEGFR1, thereby enhancing its kinase activity in cancer cells, and acts as a 
coactivator of ER in breast cancer cells240-242. Furthermore, mutated KRAS 
correlates with SMYD3 upregulation in CRC, and methylation of MAP3K2 by 
SMYD3 increases MAP kinase signaling, thereby promoting the development of 
lung and pancreatic cancer232, 243. 
Indeed, while other epigenetics drugs targeting EZH2, another component of 
the lysine(K)-methyltransferases (KMTs) family, are currently in clinical trials for 
the treatment of various human cancers, no SMYD3-specific compound has been 
identified so far. After testing several compounds, we identified a piperidine-4-
carboxamide acetanilide compound (BCI-121) that was effective in cell lines at 
low micromolar concentrations and was able to impair SMYD3-mediated H4 
methylation in vitro, showed antiproliferative properties in cancer cell lines 
overexpressing SMYD3 and, in general, replicated the effects of SMYD3-targeted 
RNAi. 
By means of molecular docking techniques we identified a small-molecule 
compound (BCI-121) which significantly inhibits SMYD3-substrate interaction 
and chromatin recruitment and is effective in reducing proliferation in various 
cancer cells types. These findings were supported with SPR analysis, where the 
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compounds and natural SMYD3 substrate H4K5, were tested for competition for 
the methylation pocket on the enzyme. 
 
Results and Discussion 
Molecular modeling & Dose-dependence of BCI-121 treatment in cells line 
Based on the crystallography structure of SMYD3, we took advantage of 
molecular design techniques to search for new small molecules that could inhibit 
its catalytic activity. Since no previous knowledge on specific SMYD3 inhibitors 
was available, our selection was based on the conformations of the substrate 
binding site and on the possibility to accommodate specific molecules.  
The substrate binding site is formed within the SET and post-SET domains and 
consists in a deep and narrow substrate binding pocket where the structure of BCI-
121 is predicted to bind. A closer look at this binding mode suggests that the 4-
carboxamide moiety of the piperidine ring is oriented toward the cofactor binding 
site and forms two hydrogen bonding interactions with Ser202. The carbamoyl 
group undergoes another hydrogen bonding between the nitrogen of the amide 
group and the backbone of Tyr239. All other interactions are basically formed with 
the hydrophobic residues that comprise the narrow binding pocket of the histone 
lysine residue, consistent with the hydrophobic nature of its alkylic side chain (Fig. 
35 and in the Supporting Information of the original article). 
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Figure 35 | Chemical scaffold and interactions made in the binding pocket of SMYD3 by BCI-121. 
These results prompted us to test the ability of BCI-121 to affect histone 
binding to SMYD3 in cell line models. Thus, we envisioned to specifically target 
SMYD3 catalytic function by means of small-molecule inhibitors in order to 
preferentially target cancer cells. 
Hence, we analyzed SMYD3 occupancy at binding sites located in the 
promoters of its target genes in two different cancer cell lines (HCT116 and 
OVCAR-3) treated or not with BCI-121. Our data confirmed that BCI-121 
competes with histones for binding to SMYD3 also in a cellular setting, as shown 
by its reduced binding to the promoter region of target genes (Fig. 36a, b). 
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Figure 36 | (a) SMYD3 binding to the promoter of its target genes is abolished by the presence of 
BCI-121 in cancer cells. ChIP was performed in HCT116 and OVCAR-3 cells treated or not with 
BCI-121 (100 mM) for 72 h. Cells were cross-linked and immunoprecipitated with anti-SMYD3 
and anti-IgG antibodies. The precipitated DNA was subjected to real-time PCR with specific 
primers, which amplify SMYD3 binding site elements of human target gene promoters (cMET, 
WNT10B, and CDK2). IgGs were used as an immunoprecipitation control. (b) Transcriptional 
activation of target genes correlates with impaired binding of SMYD3. b-actin was used for real-
time PCR data normalization. Statistical analysis was performed using Student’s t-tail test; *P < 
0.05 was considered statistically significant. 
 
In order to find the lowest concentration affecting SMYD3 activity in cell 
cultures, we established a dose-dependent curve for BCI-121 (1, 10, 30, 60, 100 
mM) and evaluated its anticancer activity in a CRC cell line (HT29) by measuring 
the cell proliferation index and by evaluating the global level of methylation at 
SMYD3-targeted (H4K5me and H3K4me2) and non-targeted (H3K27me3) sites. 
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Our results show that there is a dose-dependent relationship between SMYD3 
impairment and both inhibition of proliferation (Fig. 37a) and reduction of targeted 
methyl marks (H4K5me and H3K4me2) (Fig. 37b). 
 
Figure 37 | Dose-dependence of BCI-121 treatment in CRC cell lines. (a) BCI-121 treatment for 
48 h induces a concentration-dependent reduction of CRC cell proliferation and (b) decreases the 
global levels of targeted histone methyl marks [H4K5me, H3K4me2] and ERK 1/2 activation. A 
non-targeted methyl mark [H3K27me3] was not affected. b-actin was used as a loading control for 
immunoblotting. (c) The dose-dependent effect of BCI-121 treatment (72 h) on cell growth is 
observed in cells expressing high levels of SMYD3 (HCT116), but not in cells with low levels of 
SMYD3 (LS174T). Cell proliferation was calculated using the WST-1 assay. Statistical analysis 
was performed using Student’s t-tail test; *P < 0.05, **P < 0.01, and ***P < 0.001 were considered 
statistically significant. 
 
A similar correlation was also observed with the level of MEK-ERK signaling 
activity (Fig. 37b). Consistent with previous results, the dose-dependent effect on 
cell growth was detected in cancer cells expressing high levels of SMYD3 
(HCT116 cells). while BCI-121 treatment failed to inhibit proliferation in cancer 
cells with low levels of SMYD3 (LS174T cells) (Fig. 38c). Collectively, these data 
indicate that BCI-121 reproduces the effects of SMYD3-targeted RNAi.  
Collectively, these data indicate that BCI-121 reproduces the effects of 
SMYD3-targeted RNAi. Based on these data, we speculated that the use of 
specific inhibitors might help to gain a better understanding of the role of SMYD3 
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in tumorigenesis and could also be the basis for future pharmacological 
interventions. 
Binding competition experiments in vitro by means of surface plasmon resonance. 
In order to get further insight into the mechanisms underlying SMYD3 
inhibition by BCI-121, we performed surface plasmon resonance experiments to 
investigate the binding modes of this compound with molecular modeling 
techniques. 
The target protein SMYD3 was immobilized through an affinity capture method 
as a SMYD3-GST fusion protein to an anti-GST antibody covalently bound to a 
CM5 sensor chip. This oriented immobilization approach ensured that the histone 
binding site of SMYD3 was accessible for interaction. H4 histone binding to 
SMYD3 was analyzed at different analyte concentrations, and an affinity KD of 
1.18 · 10–5 M was determined based on the association and dissociation rate 
constants (kon = 357.7 ± 28.0 M–1 s–1; koff = 4.23 × 10–3 ± 2.9 10–5 s–1; KD = koff / kon, 
data in the supplementary material of the original manuscript). 
Then, compound BCI-121 was assessed as a potential inhibitor of 
SMYD3/histone binding. H4 histone was injected at 72.03 µM, alone or in the 
presence of BCI-121, in 1:1 and 1:2.5 [histone peptide]:[BCI-121] molar ratios. At 
these ratios, BCI-121 inhibited histone H4 binding by 36.5% and 51.0%, 
respectively (Fig 38 and table 4), indicating that the mechanism foreseen by 
docking calculation can indeed occur through competition at the histone binding 
site.  
 136  
 
Figure 38 | Representative sensorgrams for BCI-121 competing with histones protein for 
SMYD3 binding in vitro. Sensorgrams of H4 histone binding to SMYD3 alone (red trace) and in 
the presence of BCI-121 at 1:1 molar ratio (magenta) and 2.5 :1 molar ratio (blue line). 
 Response decrease (%) 
[BCI-121] : [Histone] 1st replicate 2nd replicate Total 
1 : 1 34.9 38.1 36.5 
2.5 : 1 55.2 46.8 51.0 
Table 4. Percentage of response decreasing when the histone protein binds to SMYD3 in the 
presence of BCI-121. 
 
Conclusion 
The US FDA recently approved three new epigenetic drugs for the treatment of 
specific human cancers, and small-molecule inhibitors targeting the KMT family 
component EZH2 are currently in clinical trials. However, despite the emerging 
pathophysiological role of SMYD3 in human cancer and its potential as a 
therapeutic target, no SMYD3 inhibitors have been identified so far244. A better 
understanding of the role of SMYD3 in tumorigenesis might prove useful for the 
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design of future pharmacological interventions. Indeed, a SMYD3-based 
therapeutic approach capable of inducing a cytostatic effect on different types of 
tumor cells could be a valuable tool in cancer treatment. The ability of BCI-121 to 
arrest cancer cells at the S/G2 boundary of the cell cycle suggests that this small 
molecule could improve the effects of conventional chemotherapy by acting on the 
DNA damage checkpoints, and it can be hypothesized that BCI-121 could also 
sensitize cancer cells to S/G2 phase-specific chemotherapeutic agents. Our study 
provides an important advancement in this research area, since it describes for the 
first time a non-peptide inhibitor of SMYD3. Indeed, these data represent the proof 
of principle that SMYD3 can be pharmacologically modulated by means of small-
molecule inhibitors. We believe that these results may have a strong impact on the 
identification of new molecules amenable to use as novel therapeutic agents. 
Overall, the results presented here hold the basis for the development of new 
classes of SMYD3 inhibitors for therapeutic use in different cancer types. 
Indeed, cancer cells treated with BCI-121 showed a significant reduction in 
their growth ability and accumulated in the S phase of the cell cycle, suggesting 
that SMYD3 might be required for proper cell cycle progression through the S/G2 
boundary. Efficacy of the selected compound was also demonstrated with histone 
competition experiments through SPR techniques. 
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Material and methods 
Surface plasmon resonance (SPR) 
Measurements were performed with a Biacore X100 optical biosensor (Uppsala, Sweden), 
thermostated at 25 °C. Evaluation of sensorgrams and data analysis was performed using the 
BiacoreTMX100 2.0.1 software. SMYD3 immobilization was obtained through affinity capture. 
The two flow cells were loaded independently with an anti-GST antibody using the amine coupling 
kit from BIAcore according to the standard procedure. The CM5 sensor chip was equilibrated at 25 
°C and the system was primed three times using running buffer. A mixture of 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) 0.4 M and N-hydroxysuccinimide 
(NHS). 0.1 M was freshly prepared and injected at 5 ml/min for 7 min. The anti-GST antibody was 
diluted at 30 mg/ml in sodium acetate pH 5.0 and injected at 5 ml/min for 180 sec, resulting in 
approximately 3,000 RUs for each flow cell. Injecting ethanolamine at 5 ml/min for 7 min 
deactivated the remaining active esters. The active flow cell was loaded with the SMYD3-GST 
fused protein solution, 2 mg/ml, until reaching approximately 300 RUs and the reference cell was 
loaded with an equimolar recombinant GST protein to reach approximately 150 RUs. The H4 
peptide stock solution was prepared at 128.66 µM and serial dilutions at 64.82 µM, 32.41 µM, 
16.21 µM, 1.47 µM were injected at 30 µl/min for 60 s over the surface and then the complex was 
allowed to dissociate for 720 s until reaching a level ` 2.0 RU relative to the baseline. The affinity 
KD of the H4 peptide was derived from kinetic parameters (association and dissociation rate 
constants, kon and koff). Inhibition of H4 binding to SMYD3 by BCI-121 was obtained by 
dissolving the compound in running buffer and mixing it with the histone peptide at 1:1 and 2.5:1 
ratios. The final concentrations were 72.03 µM for the histone peptide and 72.03 and 183.33 µM 
for the BCI-121 compound. The resulting solutions were injected at 30 µl/min and association was 
monitored for 100 sec, after which the running buffer was flowed and dissociation was monitored 
for 900 sec. Measurements were performed in duplicate and averaged; final results were obtained 
by subtracting the unspecific binding given by the reference flow cell and normalizing to the 
baseline injection. 
 
Molecular biology and Docking studies 
All details can be consulted on the original research article 
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Abstract 
Levamisole, an anthelmintic drug, has been increasingly employed as an adulterant 
of illicit street cocaine over the last decade; recently, the use of tetramisole, the 
racemic mixture of levamisole and its enantiomer dexamisole, was also 
occasionally observed. A new enantioselective high-performance liquid 
chromatography (HPLC) method, performed on cellulose tris(3,5-
dimethylphenylcarbamate) chiral stationary phases in normal-phase mode, was 
validated to determine the enantiomeric composition of tetramisole enantiomers in 
seized cocaine samples. Furthermore, the hyphenation of the validated HPLC 
method with a circular dichroism (CD) detection system allowed the direct 
determination of elution order and a selective monitoring of levamisole and 
dexamisole in the presence of possible interferences. The method was applied to 
the identification and quantitation of the two enantiomers of tetramisole in seized 
street cocaine samples.  
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Introduction 
Levamisole (Fig. 39) is a veterinary anthelmintic drug which was employed as 
a therapeutic agent for humans until the end of the 20th century, when it was 
withdrawn due to adverse side effects such as agranulocytosis, cutaneous 
vasculopathy and leukoencephalopathy245. 
 
Figure 39 | Chemical structures of tetramisole enantiomers; a: levamisole; b: dexamisole. 
 
 Levamisole gained forensic interest after the increase of its use as an adulterant 
in illicit cocaine samples; as a result, levamisole is now found in the majority of 
cocaine seized worldwide, linked to debilitating and eventually fatal immunologic 
effects in cocaine abusers246. The use of levamisole as adulterant is likely due to its 
physicochemical properties, which are quite similar to those of cocaine, although 
being a much cheaper and more easily accessible substance247.  
Moreover, the presence of levamisole should hypothetically enhance the effects 
of cocaine, since a possible synergism for their interaction has been proposed248. 
Therefore, the health risks associated to the use of levamisole as adulterant are 
worth highlighting, due to possible high contents in some illicit street cocaine 
samples which can eventually exceed the content in pure cocaine247. The presence 
of levamisole determines an additional health threat due to aminorex, one of its 
main metabolites249, 250. Analytical assays for the determination of levamisole have 
been reported by gas chromatography–mass spectrometry (GC–MS) in human 
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urine samples249 and by high-performance liquid chromatography–mass 
spectrometry (HPLC–MS) in cocaine samples250.  
Quite recently, the analysis on seized illicit cocaine samples showed that some 
manufacturing laboratories have begun using tetramisole, a racemic mixture of 
levamisole and its enantiomer dexamisole (Fig. 39), as a substitute for levamisole 
as adulterant. Therefore, the identification and determination of both enantiomers 
is essential for a better evaluation of the health risks arising from the presence of 
these adulterants, in view of the different biological activity of the two 
enantiomers251 and the stronger adverse effects of dexamisole in humans. 
Furthermore, the enantiomeric composition of adulterants in seized samples of 
cocaine may help determining the origin of the illicit drug251. Enantioselective 
analyses on tetramisole have already been developed and performed by capillary 
GC with flame ionization detection (FID) using fused silica columns coated with 
cyclodextrin252, by HPLC253 and capillary electrophoresis (CE)254 using 
cyclodextrins as chiral selectors, and by HPLC on polysaccharide-based chiral 
stationary phases (CSPs)254; the advantages of enantioselective separation methods 
over polarimetric methods for the determination of tetramisole enantiomers were 
also experimentally demonstrated254.  
In the following study, an enantioselective HPLC method has been validated 
and applied for the detection and determination of levamisole and tetramisole in 
cocaine samples in the presence of some of the more frequently used adulterants; a 
cellulose tris(3,5-dimethylphenylcarbamate) CSP was used in the normal-phase 
mode. To enhance the selectivity of the HPLC assay, an online HPLC–circular 
dichroism (CD) method was developed and used for the identification and 
determination of the elution order levamisole and dexamisole in seized cocaine 
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samples, in the presence of several adulterants. Indeed, the well-established 
hyphenation of enantioselective HPLC and CD detection255-258 allows determining 
the stereochemistry of the eluted fractions with high detection selectivity; this 
feature is particularly important when dealing with complex matrices80, as in the 
case of street samples of cocaine.  
 
Results and Discussion 
Enantioselective HPLC analysis  
Enantioresolution of tetramisole enantiomers  
The separation of tetramisole enantiomers was obtained on the Chiralcel OD-H 
column by using a mobile phase consisting of (n-hexane)–(2-propanol)–
diethylamine (80:20:0.1, v/v/v) at a 0.7 mL min−1 flow rate. On the Lux Cellulose-
1 column, the same mobile phase at a 1.4 mL min−1 flow rate ensured excellent 
Enantioresolution within 12 min. The elution order of the two enantiomers was 
established by injection of levamisole and tetramisole samples: dexamisole and 
levamisole were resolved with moderate enantioselectivity (α =1.18 on Chiralcel 
OD-H, 1.20 on Lux Cellulose-1). The tested columns have similar characteristics 
(same CSP, particle and column sizes) but different performances; the Lux 
Cellulose-1 column provided higher resolution and efficiency and was therefore 
chosen for the subsequent validation of the method. CD detection revealed a 
positive CD signal at 230 nm for dexamisole and a negative signal for levamisole 
(Fig. 40a).  
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Figure 40 | UV (absorbance A in mAU) and CD (ellipticity in mdeg) chromatograms for the 
enantioselective HPLC analysis of tetramisole. (a) standard mix of tetramisole and common 
adulterantc found in street cocaine samples. (b) seized street cocaine sample containing levamisole 
(X3). (c) seized street cocaine sample containing tetramisole (X1). Analytes: a: levamisole; b: 
dexamisole; c: solvent; d: cocaine; e: lidocaine; f: norcocaine; g: phenacetin; h: procaine; i: 
benzocaine; j: caffeine. Details of HPLC condition in material and methods. 
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Method validation  
The developed enantioselective HPLC method shows appropriate separation 
selectivity: cocaine, norcocaine, lidocaine, phenacetin, procaine, benzocaine and 
caffeine did not interfere with the elution times of tetramisole enantiomers (Fig. 40 
a, and the Supporting Information of original articles). The calibration curve 
derived from the average peak areas for levamisole in the selected concentration 
range (a = 13.007; b = 9.763) provides satisfactory values of correlation and 
quality coefficients (r2 = 0.9991; QCmean = 3.094 %), and therefore the method 
shows a high degree of linearity. The resulting LOD and LOQ values (LOD = 0.84 
g mL−1; LOQ = 2.52 g mL−1) are adequately low. Moreover, the method shows 
reasonable intra- assay precision (peak area RSD = 0.64%), inter-assay precision 
(peak area RSD = 1.16 %), and accuracy (average recovery: 101.71 %; RSD = 
1.02 %); further details on the results obtained in validation assays are reported in 
the Supporting Information of the original article. 
UV and CD spectroscopy  
On-line UV and CD measurements showed a very simple spectroscopic 
behavior for tetramisole enantiomers: broad, mirror-image CD bands in the 270–
220 nm region, positive for dexamisole and negative for levamisole, were 
observed. Off-line spectroscopic analysis on levamisole hydrochloride in 2-
propanol showed a clear hypsochromic shift of the CD band with respect to the 
stopped-flow spectrum on levamisole, but the sign of the band is unchanged and 
the intensity is comparable (Fig. 41).  
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Figure 41 | On-line UV (absorbance A in AU) and CD (ellipticity in mdeg) spectra of levamisole 
(dark) and dexamisole (light), compared to the off-line spectra of levamisole hydrochloride in 2-
propanol (dashed). 
 
 
Street drug samples analysis  
The presence of levamisole or tetramisole was observed in most of the seized 
cocaine samples analyzed; the quantitation of levamisole/tetramisole and cocaine 
for a limited set of seized cocaine samples containing levamisole or tetramisole is 
reported in Table 5.  
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Sample Levamisole (wt%) Tetramisole (wt%) Cocaine (wt%)a 
X1 17.97  42.41 
X2 2.36  6.20 
X3  5.93 60.78 
X4  11.70 30.40 
Table 5. Content of levamisole/tetramisole and cocaine in a set of street cocaine samples, given as 
percentage by weight (wt%). a. Determined with method reported in “Recommended Methods for 
the Identification and Analysis of Cocaine in Seized Materials (ST/NAR/7/REV.1), United Nations 
Office on Drugs and Crime (UNODC), Vienna, 2012”. 
 
Interestingly, the content in levamisole was extremely variable for the analyzed 
samples, irrespective of the content in pure cocaine. The CD detection system has 
a much higher selectivity with respect to diode array detection, since the 
monitoring is limited to chiral, non-racemic compounds. Figure 40a shows the CD 
and UV chromatographic profiles for the enantioselective HPLC analysis of a 
mixture of tetramisole and possible interfering analytes: under the adopted 
experimental conditions, only the two enantiomers of tetramisole are detected in 
the CD profile. The selectivity provided by CD detection was particularly useful 
when applied to street cocaine samples, allowing an easy monitoring of levamisole 
and dexamisole. The analyses of two seized cocaine samples are reported in Figure 
40b and c, with both the UV and CD chromatographic profiles. One sample shows 
the presence of levamisole, being the only analyte monitored by the CD detection 
system (Fig. 40b), while the second sample shows the presence of tetramisole, as 
selectively monitored by CD (Fig. 40c).  
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Conclusions  
An enantioselective HPLC method has been validated for the identification and 
determination of tetramisole enantiomers, levamisole and dexamisole, and then 
applied to the analysis of seized samples of cocaine. Most of the examined street 
samples showed the presence of levamisole or tetramisole: the content in 
adulterant was relatively high in some cases, when compared to the amount of 
pure cocaine in the illicit drug. The use of a CD detection system allowed to 
monitor levamisole and dexamisole with very high selectivity, even in the case of 
street cocaine samples, where several additional compounds are present. The 
usefulness of the method arises from the increasingly common use of both 
levamisole and tetramisole as adulterants in street cocaine: a reliable detection and 
determination of the two enantiomers of tetramisole is therefore essential to 
evaluate the health risks related to the composition of cocaine samples, to promote 
a deeper understanding on the causes of acute intoxications, and provide useful 
comparative information on the origin of seized samples. 
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Materials and methods 
Materials  
 
Compounds rac-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]- [1,3]thiazole hydrochloride 
(tetramisole), (−)-(S)-6-phenyl- 2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole hydrochloride 
(levamisole), N-(4-ethoxyphenyl)acetamide (phenacetin), 2-(diethylamino)-N-(2,6-
dimethylphenyl)acetamide (lidocaine), 2-(diethylamino)ethyl 4-aminobenzoate hydrochloride 
(procaine), ethyl 4-aminobenzoate (benzocaine) and 3,7-dihydro-1,3,7- trimethyl-1H-purine-2,6-
dione (caffeine) were purchased from Sigma–Aldrich (Milan, Italy). Analytical-grade solvents (n-
hexane, 2-propanol, ethanol 99.7% and diethylamine) were purchased from Sigma–Aldrich (Milan, 
Italy). Stock solutions of analytes were prepared in ethanol at a 1.00 mg mL−1 concentration. The 
standard solutions used for method validation were prepared by dilution of stock solutions with 
mobile phase.  
 
Enantioselective HPLC analysis  
 
Instrumentation  
The enantioselective HPLC analysis was carried out on a chromatographic system consisting of a 
Jasco (Tokyo, Japan) PU-980 HPLC pump, a MD-910 diode array detector, a LG-2080-02 ternary 
gradient unit, a DG-2080-53 degasser, a Jones (Lakewood, CO, USA) model 7955 HPLC column 
chiller, a Rheodyne 7725i syringe loading injector and a 20 L sample loop; a Chiralcel® OD-H col- 
umn (CSP: cellulose tris(3,5-dimethylphenylcarbamate) coated on silica gel; 250 × 4.6 mm I.D., 5 
m particle size; Daicel, Illkirch, France) and a LuxTM Cellulose-1 column (CSP: cellulose tris(3,5- 
dimethylphenylcarbamate) coated on silica gel; 250 × 4.6 mm I.D., 5 m particle size; Phenomenex, 
Castel Maggiore, Italy) were used. CD detection was implemented by connecting the system to a 
Jasco J-810 spectropolarimeter equipped with a 10 mm pathlength HPLC flow cell and a Rheodyne 
7010 injector set up as a three-way valve for stopped-flow measurements. Single-wavelength 
chromatograms were recorded at 230 nm in both diode array and CD detection modes; CD 
detection was carried out using a 2s data pitch, a 5 nm spectral bandwidth and a 2 s time constant.  
 
 
 150  
Chromatographic conditions  
The enantioselective HPLC analysis was performed using a mobile phase consisting of a n-hexane–
2-propanol mixture (80:20, v/v) in isocratic conditions; 0.1% (v/v) diethylamine was added to the 
mobile phase to neutralize the cationic forms of analytes and improve the chromatographic 
resolution. Constant flow rates (0.7 mL min−1 on Chiralcel OD-H column, 1.4 mL min−1 on Lux 
Cellulose-1) and column temperature (15° C) were used.  
 
Method validation  
The enantioselective HPLC method was validated using the Lux Cellulose-1 column and diode 
array detection. Selectivity was assessed by analysis of a 150 µg mL−1 standard solution of 
tetramisole hydrochloride; the relevant chromatographic parameters (capacity factor k, number of 
plates N, asymmetry factor A, selectivity α and resolution R) were determined according to the 
half-height method using the Jasco ChromNav software. Interference from other analytes was 
investigated by analysis of a mix of frequent adulterants found in street cocaine samples (lidocaine, 
phenacetin, procaine, benzocaine and caffeine) with tetramisole; different concentrations were used 
depending on the spectroscopic response of analytes at 230 nm. Capacity factors for cocaine and its 
metabolite norcocaine were derived from the chromatograms of analyzed street cocaine samples; 
their identity was confirmed by GC–MS analysis (Figs. S1–S3 in the Supporting Information of the 
original article) according to “Recommended Methods for the Identification and Analysis of 
Cocaine in Seized Materials (ST/NAR/7/REV.1), United Nations Office on Drugs and Crime 
(UNODC), Vienna, 2012”. Linearity (n = 3) was evaluated by analyzing six standard sam- ples of 
levamisole hydrochloride (6.25, 9.375, 18.75, 37.5, 75 and 150 µg mL−1); triplicate injections were 
performed for each solution. A calibration curve was obtained by plotting the peak areas (in mAU 
min) against the correspondent concentrations of neutral analyte (µg mL−1) and applying a linear 
regression model (y = a + bx), for which the correlation coefficient (r2) and the quality coefficient 
(QCmean) were determined259, 260. Sensitivity was assessed by calculating the limit of detection 
(LOD) and limit of quantitation (LOQ) for levamisole from the calibration curve using the standard 
deviation of the y-intercept (sa) and the slope (b) obtained by linear regression (LOQ = 10sa /b; 
LOD = LOQ/3). Intra-assay and inter-assay precision (n = 6) was determined by repeated injections 
of a 75 g mL−1 standard solution of levamisole hydrochloride. The average capacity factors and 
peak areas, with the corresponding relative standard deviations (%RSD), were determined for both 
assays.  
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Accuracy (n = 3) was evaluated by spiking a 0.5 mg mL−1 solution of seized street cocaine powder 
(see next subsection for sample preparation) with three different concentrations (60, 75 and 90 g 
mL−1) of levamisole hydrochloride; duplicate injections were performed for each sample. The 
average recoveries and relative standard deviation (% RSD) were determined for each 
concentration.  
 
Street drug samples analysis  
The validated HPLC method with diode array detection was applied to the analysis on samples of 
street cocaine powders (X1–X4) seized by Italian law enforcement agencies. Aliquots of 100 mg of 
finely ground samples were dissolved in ethanol by sonication to obtain a concentration of 10 mg 
mL−1, diluted to 1 mg mL−1 with mobile phase and immediately injected in the HPLC system. The 
content of levamisole and tetramisole were determined by means of peak area interpolation with 
calibration curves and expressed as percentage by weight (wt %) of street cocaine sample. 
 
UV and CD measurements 
Off-line UV and CD spectra of levamisole hydrochloride (1 mM in 2-propanol) were recorded at 
25° C in the 300–195 nm spectral range on a Jasco (Tokyo, Japan) J-810spectropolarimeter 
equipped with a PTC-423S Peltier-type temperature control system, using a 0.5 mm pathlength 
cell. Measurements were carried out at 0.2 nm intervals using a 2 nm spectral bandwidth, a 20 nm 
min−1 scan rate and a 2 s time constant. On-line UV and CD spectra of levamisole and dexamisole 
were recorded in the 300–220nm range by stopped-flow measurements, using a 0.5 nm data pitch, a 
2 nm spectral bandwidth, a 200 nm min−1 scan rate and a 1 s time constant.  
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11. Conclusion and Perspective 
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Conclusion and future perspective 
In the present dissertation, two spectroscopic analytical technologies – surface 
plasmon resonance (SPR) and circular dichroism (CD) – were described in term of 
detection principle, instrumentation available, experimental set-up and data 
analysis. Advantages and limitations of each approach are critically reviewed and 
their relevance for the field of pharmaceutical science is discussed. Description is 
complemented by a short presentation of the theory behind biological activity of 
exogenous and endogenous compounds in living organisms and the role that 
pharmaceutical analysis exerts in drug discovery. Then, few selected experimental 
applications of SPR and CD methodologies, carried out during the course of the 
PhD program, are illustrated and commented. 
In particular, cross-species (human and rat) serum albumins binding for two 
naturally occurring triterpenoids, Cucurbitacin E and I (CucE and CucI) were 
evaluated in perspective of using the two compounds as therapeutics. The steady 
state and kinetic analysis of SPR sensorgrams for Cuc–serum albumins complexes 
unveiled a previously unreported binding event between CucI and human serum 
albumin (HSA), with CucI showing a 3-fold lower affinity than CucE. From KD 
values measured all compounds were classified as high affinity binders for both 
serum albumins. However, both compounds bind slightly tighter to rat serum 
albumin (RSA) with respect to HSA. CD spectroscopic analysis showed that CucE 
and I are able to modulate the binding of biliverdin to serum albumins, as observed 
by the concentration-dependent change in intensity of the positive ICD band of 
biliverdin upon titration with cucurbitacin. Two different behaviors were detected, 
positive modulation for HSA and negative for RSA. Overall, the findings 
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suggested that a different in vivo action for CucE and I in the two different animal 
species could exist and it needs to be carefully assessed in translational medicine. 
The binding of the pleiotropic gene regulator of Helycobacter Pylori NikR 
(HpNikR) to the operator region of the urease promoter (OPureA) was investigated 
through an extended SPR experimental set-up in combination with isothermal 
titration calorimetry. An active surface bearing immobilized OPureA was prepared 
via affinity capture procedure and its functionality was extensively assessed. A 
kinetic analysis of the biorecognition event revealed an isomerization of the 
HpNikR–OPureA complex occurring over time. After the first encounter between 
the two interactants to form the first complex, it undergoes a conformational 
rearrangement that in the presence of stoichiometric Nickel (II) ions in the 
environment leads to high-affinity binding. Combination of the new SPR data with 
previous NMR, light scattering and molecular dynamics simulations data was able 
to confirm that the stoichiometric presence of Ni(II) “unlock” HpNikR structure 
and allows it to span the surrounding more efficiently in search of the dsDNA 
sequence. This behavior allows the bacteria to finely regulate expression of 
enzyme related to the Nickel homeostasis in response to high concentration of the 
metal in the environment. 
The combination of enantioselective high performance liquid chromatography 
(HPLC), electronic circular dichroism (ECD) spectroscopy, and time-dependent 
density functional theory (TD-DFT) calculations was successfully employed to 
characterize the absolute stereochemistry of a trans-3-arylglycidic acid derivative. 
In perspective of using this natural building block as starting material for the 
production of polymers endowed with pharmaceutical activity it is essential to 
know its absolute configuration. In the present study the full stereochemical 
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characterization was achieved through the stopped-flow method. With this 
approach the fractions eluting from the HPLC were directly trapped into a tailor-
made sample chamber and the CD spectra recorded in the 350–200 nm spectral 
range. With this method the step of collecting pure enantiomers and dry the 
solvent out was excluded, drastically reducing the likelihood of degradation for the 
collected fractions. 
 SPR competition assay was employed to monitor the inhibition capacity of a 
selected small molecule (BCI-121) towards an epigenetic regulator involved in 
several cancer malignancies, SMYD3. Through molecular docking techniques the 
methylation gorge of the enzyme was inspected and a molecule with suitable 
chemical scaffold was synthesized. The compound was tested on a selected cell 
line, and a concentration-dependent reduction of the proliferation of tumor cells 
was observed, indicating a potential therapeutic effect could exist. The mode of 
action for the drug was then tested via SPR assay, in which BCI-121 and SMYD3 
natural substrate H4K5 were injected together over a SMYD3 bioactive surface. A 
lower SPR response was detected when the histone residue binds to the protein in 
the presence of BCI-121, suggesting that a competition for the same binding site 
could indeed take place and be the main mechanism of inhibition. 
Combination of HPLC-CD and ECD spectroscopy was employed to determine 
the presence of two adulterants dexamisole and its enantiomer levamisole in seized 
street cocaine samples. The use of a CD detection system allowed monitoring 
levamisole and dexamisole with very high selectivity, even in the case of street 
cocaine samples, where several additional compounds are present. This practical 
method developed here provides a fast means to evaluate the health risks related to 
the composition of cocaine samples, to promote a deeper understanding on the 
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causes of acute intoxications and to provide useful comparative information on the 
origin of seized samples. 
The selected applications of SPR and CD spectroscopies illustrated in the 
present dissertation serve as a small sample of all the possibilities that the two 
approaches provide.  
It is important to stress that SPR and CD spectroscopies greatly benefit from 
their combination and synergy since the two techniques allow extrapolating 
complementary information on the same biological system; SPR can provide 
dynamic data on biorecognition events, while CD can provide conformational 
insight on the guest-host complex in solution.  
They demand for different material consumption, as SPR can perform a whole 
analysis with few µg of both interactants while CD needs higher material 
consumption. Nonetheless, CD can provide valuable information on the 
conformation of complexes in solution and could, in principle, be used to “see” the 
conformational rearrangement indirectly measured with SPR assays. If 
spectroscopic properties are favorable the isomerization of a bimolecular complex 
could be follow in real-time as a change in optical activity, and the rate for the 
conformational rearrangement quantified and directly related to SPR 
measurements. Moreover, CD is solely based on light absorption of species in 
solution while SPR detection principle relies on specific adsorption phenomena at 
the surface of a sensor chip. Therefore, while the latter is not able to discern what 
causes refractivity change, the former will only produce signal upon specific 
binding, resulting in a highly selective detection method and a cleaner means to 
eventually extrapolate affinity constants.  
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As conclusive remarks, is important to note that the SPR assays developed 
during the course of the PhD program and presented in this thesis can serve as 
platform for inhibitor screening.  
Regarding SMYD3 epigenetic regulator, the findings reported in this 
dissertation prompted further evaluation of molecules’ libraries through SPR 
analysis. The experimental set-up was expanded and different isoforms of the 
enzyme were immobilized taking advantage of different chemistries. Other 
binding partners were tested for the binding to the protein and encouraging 
outcomes were used as a background research to apply, and subsequently obtain, a 
research grant from Italian Association for Cancer Research – AIRC (starting 
2017).  
The SPR assay developed for the monitoring of HpNikR – OPureA interaction is, 
at best of my knowledge, the only SPR method to probe inhibition of protein–
dsDNA binding, as this type of interactions were previously defined as 
undruggable. The competition assay employed to validate the protein–dsDNA 
recognition event, can be easily translated in an inhibition assay employing soluble 
molecules with potential therapeutic properties. If binding between HpNikR and 
OPureA is prevented, key Nickel-related enzymes cannot be synthesized and 
considering that most of them are pathogenic factors for Helycobacter Pylori, this 
could result in a highly selective therapeutic effect. 
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